Stakeholders Contributing to Commercialization of A Radical Innovation at Global Markets: A Single Case Study by Engez, Anil
 
 
 
 
 
 
 
 
 
ANIL ENGEZ STAKEHOLDERS CONTRIBUTING TO COMMERCIALIZATION OF A RADICAL INNOVATION AT GLOBAL MARKETS: A SINGLE CASE STUDY 
 
Master of Science Thesis 
 
 
 
 
 
 
 
 
Examiner: Associate Professor Leena Aarikka-Stenroos  Examiner and topic approved by the Faculty Council of the Faculty of Business and Built Environment on 6th August 2018 
i  
ABSTRACT 
ANIL ENGEZ: Stakeholders Contributing to Commercialization of A Radical In-novation at Global Markets: A Single Case Study Tampere University of Technology Master of Science Thesis, 79 pages February 2018 
Master’s Degree Programme in Industrial Engineering and Management Major: International Sales and Sourcing Examiner: Associate Professor Leena Aarikka-Stenroos  Keywords: Commercialization, innovation marketing, stakeholder, innovation management, functional food, stakeholder collaboration, global markets 
Even though successful commercialization is of great importance to innovative firms, we do not yet know how diverse stakeholders can contribute to commercialization of a radi-cal innovation that require particular market creation support. To explore this phenome-non and to develop the theory of the research field, this study aims to answer the following research questions: Who are the relevant stakeholders that can contribute to commercial-ization? What kind of activities do stakeholders employ for effective commercialization? What are the motives of stakeholders to be involved in along commercialization? How stakeholders and their activities are interconnected? 
To answer these questions, a single case is analyzed, which is a functional food i.e. a novel product category between food and medicine at global market settings. The func-tional food product is a margarine that helps lowering cholesterol, which was invented by a food manufacturing company located in Finland. The case relies on qualitative inter-views with regulatory bodies, doctors, opinion leaders, licensing partners, marketing managers and scientists as primary data source and extensive secondary data, which mainly consists of books and academic journal articles. Seven semi-structured interviews were conducted and all the interviews were recorded and transcribed by the author. The data is used to analyze the activities of diverse stakeholders that shaped the success of commercialization process of the innovation throughout the years. In addition to the ac-tivities, the motives and interests of the stakeholders for being involved in the commer-cialization process were also examined. 
Results uncover the contributions by diverse stakeholders to commercialization and mar-ket creation. Stakeholders perform activities such as drafting new legislation and food labelling for health claims, conducting safety assessments, product development, finding 
out consumers’ preferences, communicating benefits of the product to several actors for adoption, gaining the trust of healthcare professionals and patients, and revealing the pos-itive health effects of the ingredient. The results indicate that the motives of such activities are ensuring well-being of people, creating new business ecosystems, contributing to the economy, and creating awareness among public towards a healthy diet and lifestyle, which facilitate the emergence of a market. This study contributes to marketing and in-novation management literature and generates practical advice for managers who com-mercialize (radical) innovations.  
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1. INTRODUCTION 
1.1 Background 
Even though successful commercialization is of great importance to innovative firms, the 
topic has remained unstudied, as research and development (R&D) tend to attract more 
research interest (e.g Driessen & Hillebrand, 2011). The increasing body of commercial-
ization research has recently acknowledged that commercialization efforts by the innova-
tor firm can be facilitated by diverse stakeholders who can support the adoption and set 
up markets for the novelty (e.g. Chiesa & Frattini, 2011; Aarikka-Stenroos et al. 2014). 
Commercialization is indeed a critical area in the innovation process (Chiesa & Frattini, 
2011), and it highly affects the innovation success and performance. Commercial success 
of a new product highly depends on the approaches that are adopted by the company to 
commercialize it and launch it in the market (Schilling, 2005). Companies have to plan 
the launch strategy of a new product thoroughly and in advance. For a product, being 
technically and functionally superior to the competing ones does not always mean that it 
would also succeed in commercialization and market launch. (Hartley, 2005). A special 
effort should be put in these processes regardless of the technical success potential of the 
product. Effective use and active involvement of stakeholders determines the success of 
the commercialization and market launch of a new product (Aarikka-Stenroos et. al., 
2014). 
Chiesa and Frattini (2011) points out that impact of commercialization choices (timing, 
positioning, and choice of distribution channels) on the innovation’s market performance 
has been largely neglected in previous researches. They remark that the variables that 
affect the success of commercialization of innovations are timing, targeting and position-
ing, inter-firm relationships, product, distribution, advertising and promotion, and pric-
ing. According to them, companies operating in high-tech business usually fail in com-
mercialization due to the lack of support from the innovation’s adoption network and 
negative post-purchase attitude of the innovation’s early adopters, which draws the atten-
tion on the need of more careful and systematic approach in commercialization processes 
that companies must employ. 
Commercialization process of a new product or technology might take longer time than 
expected and it is usually not so common to see a product that achieved success on the 
first try (Lynn et. al., 1996). Commercialization is the least well-managed area of the 
innovation process and the emphasis is more directed on research and development ac-
tivities (Cooper, 2011). Commercialization activities have importance as much as re-
search and development activities and must be examined in detail for the market success 
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of a product. These activities must be conducted with networked market actors and new 
product must attract stakeholders for the diffusion of innovation in market (Talke & 
Hultink, 2010).  
Many new organizations seek growth in international markets by expanding their activi-
ties abroad. Although expanding business abroad carries high risks due to the exposure 
to liabilities of foreignness and outsidership (Johanson and Vahlne, 2009), once it is exe-
cuted carefully and planned, it has a huge potential for growth. In order to mitigate liabil-
ities, companies should actively build and leverage network relationships to access and 
mobilize external resources in foreign markets (Coviello, 2006). Symeonidou et. al. 
(2017) state that based on the commercialization strategy that the company adopts, the 
level of the need to build these network relationships changes. This choice of strategy 
highly concerns the technology-based new ventures, whose business is based on creating 
and exploiting intellectual property (Onetti et al., 2012). There are three types of com-
mercialization strategies a company can choose, which are product based, intellectual 
property (IP)-based, and hybrid commercialization strategies. Based on the findings of 
Symeonidou et. al. (2017), companies using IP based strategy are more likely to succeed 
in international markets due to the less cost and difﬁculty of accessing value chain re-
sources abroad.  
The requirement of learning about markets is building a diverse network of relationships 
with stakeholders (Musteen et al., 2014). Identifying and involving multiple stakeholders 
in commercialization activities is crucial as the support from them helps an innovatio n 
spread throughout the target markets. Hillebrand et al. (2015) emphasize the systemic 
perspective of a focal firm to see the contribution of single actors in stakeholder systems. 
Systems thinking aims to identify all the stakeholders in the system and to explore how 
single actors are interconnected (Vargo & Lusch, 2011). Furthermore, the studies on the 
effects of diversity of actors lacked attention especially in the development of collabora-
tive innovation and rather it has been focused on strategy and organization, as well as the 
processes of innovation diffusion and implementation (Corsaro et. al., 2012). Even 
though the studies has discovered the actors who influence commercialization processes 
(Hult et. al, 2011; Kull et. al., 2016; Plouffe et al., 2016; Reypens et. al., 2016; Zeng et 
al., 2010), there is a need for a detailed empirical analysis of the relevance of diverse 
stakeholders along the commercialization and demonstrating the clear activities of actors 
around an innovator firm that contribute to commercialization, indicating the linkage of 
single actors within the system. In line with this need, this thesis will explore the different 
commercialization activities that takes place among various stakeholders such as regula-
tors, individual parties, research organizations, licensing partners, opinion leaders, doc-
tors, and marketing managers in functional food industry, which provides support and 
resources (Ritter and Gemünden, 2003). It will also analyze the motives, priorities, inter-
ests, and interactional goals of organizations. 
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1.2 Objective 
In commercialization, there are various types of stakeholders with different expectations, 
who are interested in the development of a product. Stakeholders not only contribute to 
research and development, but also to the commercialization process of a product 
(Aarikka-Stenroos et. al., 2014). In order to be successful in markets, a strong collabora-
tion among these stakeholders is needed. Companies must have access to resources, 
knowledge and relationships to gain a competitive position in domestic market or foreign 
markets (Denk et al., 2012). This is due to the need of utilizing the stakeholders for gain-
ing credibility and creating awareness. This leads to the main question of the thesis… 
…How do different stakeholders influence the success of commercialization of an 
innovation? 
Main research question can be solved by answering these sub-questions: 
 Who are the relevant stakeholders that can contribute to commercialization? 
 What kind of activities do stakeholders employ for effective commercialization? 
 What are the motives of stakeholders to be involved in along commercialization? 
 How stakeholders and their activities are interconnected? 
Stakeholders have different goals and expectations from participating in such relations. 
The goals might be revenue increase or improving well-being of communities. By under-
standing these goals clearly, innovator company would be able to know the involved 
stakeholders better and align its goals with their partners. Scientific research in the area 
of commercialization mostly focuses on the activities that stakeholders perform. This the-
sis focuses on a more comprehensive study on stakeholder motives and the interactions 
between them to better understand what aspects drive the stakeholders’ involvement in 
commercialization processes. Thus the objective of the thesis is… 
…to understand why stakeholders intend to be involved in commercialization pro-
cesses of a new product, to learn more about the activities they perform, and to 
analyze the interactions between these stakeholders during commercialization ac-
tivities. 
To address this objective, this thesis applies a single case study in functional food industry 
in Finland and reviews the literature concerning commercialization, commercialization 
activities, functional foods, market strategy, market categorization, multi-actor approach, 
stakeholder types, and network collaboration. In order to answer the proposed research 
questions, it is more appropriate to focus on one focal organization and analyze the stake-
holders around it that affect its commercialization outcomes. Single case studies, in par-
ticular, provide an empirically-rich, holistic account of specific phenomena (Yin, 2003). 
Therefore, single case study method lets us examine stakeholder activities in more detail 
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to capture the small details with qualitative analysis. In our research, single case study is 
a better approach compared to the multiple-case study that includes several organizations, 
which would have made the research more scattered. As the industries such as medical 
equipment or functional food involve sensitive content, the market launches of the prod-
ucts in these industries have difficulties in some countries regarding regulations as the 
health is a concern. For this reason, it also lets us include regulators and scientists in the 
research and study their activities and motives, which increase the stakeholder diversity 
in our study for providing different perspectives on commercialization activities. Since 
the functional food products caused controversies regarding the meaning of the function-
ality between food and medicine, it provides a distinctive base to study various stakehold-
ers involved.  
1.3 Structure 
The structure of the thesis is divided to six chapters to answer the research questions. 
Introduction is followed by theoretical background, research methodology, research re-
sults, summing up results and discussion, and conclusions chapters.  
In the theoretical background chapter, definitions of commercialization and various com-
mercialization activities are discussed. Furthermore, commercializing a functional food 
innovation, multi-actor approach in commercialization, different types of stakeholders, 
their relationship with each other in a network are explained in more detail. In the third 
chapter, research methodology of the study is presented. In results chapter, the data ob-
tained from qualitative interviews that clarifies the relevant stakeholders in functional 
food industry, their activities and motives are presented. In fifth chapter, the summary of 
the results and discussion are presented. The last chapter concludes the thesis, demon-
strates theoretical contribution, managerial implications, and limitations and future re-
search. Table 1 below represents the paths to answer the main research question. 
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Table 1. Structure of the thesis. 
Main Research Question: 
How do different stakeholders influence the success of commercialization of an innovation? 
 
 
Theoretical Background: 
Sub-question 1: Who are the relevant stakeholders that can contribute to commercialization?    
             2.5 Stakeholders in New Product Development 
             2.7 Stakeholders That Influence the Diffusion of Innovations 
Sub-question 2: What kind of activities do stakeholders employ for effective commercializa-
tion? 
             2.1 Definition of Commercialization             
             2.2 Commercialization Activities 
             2.3 Commercializing A Functional Food Innovation 
Sub-question 3: What are the motives of stakeholders to be involved in along commercializa-
tion? 
              2.6 Business Networks in Commercialization  
Sub-question 4: How stakeholders and their activities are interconnected? 
              2.4 Multi-Actor Approach in Commercialization     
 
 
Research Methodology: 
Research design, data gathering, data analysis, introducing the case company, research pro-
cess, evaluation of the research. 
Research Results: 
4.1 Regulatory Environment 
4.2 Scientists 
4.3 Research Organizations 
4.4 Experts as Opinion Leaders 
4.5 Marketing Managers 
4.6 Licensing Partners 
 
Summing Up Results and Discussion: 
Summary of the research results, and providing answers to research questions. 
Conclusions: 
Conclusions of the thesis, theoretical contribution, managerial implications, limitation and sug-
gestions for further research. 
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2. STAKEHOLDERS IN COMMERCIALIZATION OF INNOVATIONS 
2.1 Definition of Commercialization 
Commercialization involves all the activities that are performed with the aim of dissemi-
nating the innovation in the market or to several markets, and generating profits from it 
(Costa et. al., 2004; Crawford & Di Benedetto, 2008). It is a broad term that must be taken 
into account during innovation process. In the innovation process, commercialization ac-
tivities should be performed concurrently with the research and development activities, 
in order to obtain a positive market response and to eliminate the market uncertainties 
(O'Connor, Ravichandran, & Robeson, 2008; Coviello & Joseph, 2012; Aarikka-Stenroos 
& Lehtimaki, 2014). In literature, there is a tendency to use the terms launch and com-
mercialization for the same context in a new product development (NPD) process. In fact, 
these two words are not the same and their definitions are different. There is a need to use 
these definitions clearer to prevent any confusions and misunderstandings regarding the 
terms (Lehtimäki et. al., 2008).  
Launch is more often related to new products, whereas commercialization is linked to 
new technologies, concepts and products. Launch is usually considered as the last stage 
of NPD and it is described as a step or an activity in NPD. Systematic approach of product 
introduction involves planning of marketing communication, internal trainings, global 
launch, and distribution (Lehtimäki et. al., 2008). By using the term “new product devel-
opment”, it is emphasized that the focus of launch is on products, not on technologies. In 
order to use the technologies in the context of launch, there has to be a product application 
in relevance with the technology. Nevertheless, oftentimes launch refers to the product 
itself. It should be noted that when a product launch takes place, other products of the 
company might be cannibalized. A balance in focus between products must be ensured. 
It is suggested for companies to emphasize on the strategy to make the decision on which 
products to focus more, before the planning of launch phase. 
In the development process of a product, decisions, technical activities and commerciali-
zation interact and evolve together (Prenkert, 2012). Aarikka-Stenroos & Lehtimäki 
(2014) state that commercialization and other activities of the innovation process are com-
plementary, concurrent and mutually linked. They also point out that commercialization 
concerns the level of innovativeness of a technology and it takes into consideration how 
to bring novel technologies into profit making position and disseminating the innovation 
in the market. The level of innovativeness increases as the introduction of the innovation 
is related to a technology rather than the concrete product. Also, the time needed for ac-
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tivities concerning product introduction is less and the processes are less complex com-
pared to the technology introduction. In order to provide detailed definitions of commer-
cialization, several viewpoints by various authors are listed in Table 2 below. 
Table 2. Definitions of commercialization. 
Author,Year Commercialization Definition 
Aghajani and 
Yazdanpanah, 2005 
Commercialization is the process of transferring knowledge and 
technology from research centers to the industries and new busi-
nesses 
Bhuiyan, 2011 
Commercialization contributes to job creation, technology advance-
ment, a higher standard of living and most importantly economic 
growth 
Bozeman, 2000 
Commercialization enables technology transfer through published 
articles or papers, patents, licensing, attracting technology, informal 
methods, human resource exchange, presenting technology at the 
place, and development of generative companies 
Chiesa & Frattini, 
2011 
Marketing an innovation with the aim of 
converting it into a profit-making position in the marketplace 
Costa et al., 2004 
Entails both marketing strategy planning and subsequent implemen-
tation 
Crawford & Di Bene-
detto, 2008 
Conventionally refers to the moment of facing markets and dissemi-
nating the innovation 
Guiltinan, 1999 
Commercialization involves diverse strategic and tactical marketing 
tasks such as demonstrations, advertising, brand development, pro-
motional events, organizing distribution, and gathering customer 
feedback 
Hauser & Dahah, 
2008 
Commercialization assists companies to utilize economies of scale, 
to leverage their resources and to improve their reputation 
Hultink et al., 1997 
Internally consistent set of both strategic and tactical decisions that 
define how the new product is positioned and ultimately introduced 
into the market 
Jolly, 1997 
Commercialization comprises the development of the product/con-
cept, its successful launch, and interaction activities with potential 
buyers that demonstrate its potential benefit 
O'Connor et al., 2008 
Commercialization is often conceptualized as a separate late 
stage/phase of the innovation process comprising the front end or 
ideation and technical development 
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These definitions all stress that commercialization involves a development process of an 
innovation, as well as marketing tasks and the product launch. It is pointed out that re-
gardless of the success potential of the product innovation, all companies need support 
from their adoption network from different types of stakeholders to execute an efficient 
commercialization operation. 
Challenges in commercialization such as technology innovativeness, customer behavior, 
and marketing (Costa et al., 2004) causes adoption barriers among customers (O'Connor, 
1998) and stakeholders (Aarikka-Stenroos & Sandberg, 2012), and compels the firm to 
deal with stakeholders that the company is not familiar of (Garcia & Calantone, 2002). 
These challenges exist primarily due to technological, customer, and marketing disconti-
nuities (Aarikka-Stenroos & Lehtimäki, 2014).  
Technological discontinuity is caused by the introduction of new technological environ-
ment for operations, and new processes, which changes the product design and as a result, 
have an impact on the customer’s consumption patterns (McNally et al., 2010). Customer 
discontinuity resulting in adoption barriers are mainly caused by difficulties of under-
standing the benefits (Veryzer, 1998), leading the customers to not knowing and not want-
ing (O'Connor, 1998). Marketing discontinuity represents the situations when companies 
start to operate in new marketing domains. This concerns the changes in product category, 
competitors, distribution channels, or customer base (McNally et al., 2010).  
2.2 Commercialization Activities 
Commercialization activities of the innovator firm require high levels of involvement of 
the stakeholders. Therefore, the success of the commercialization is highly linked to the 
activities stakeholders perform (Story, Hart, & O'Malley, 2009). For a successful com-
mercialization process, firms need to find a way to address the customer expectations in 
relevance with the innovation, build awareness in the market by effective promotion, ed-
ucate customers and organize special events as well as trials (Aarikka-Stenroos & Sand-
berg, 2012). Companies need to acquire resources and have a broad knowledge of the 
new markets (Costa et al., 2004; Lynn et al., 1996; O'Connor et al., 2008) to make use of 
a potential opportunity of innovation in that market. The major commercialization activ-
ities can be considered as defining a marketing strategy, targeting, segmentation, posi-
tioning decisions and the identification of competitors (Costa et. al., 2004). Table 3 below 
shows different approaches in commercialization in literature presented by several au-
thors and shows how networks are linked to commercialization. 
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Table 3. Focus areas of commercialization. 
Author,Year Research Focus Approach in Commercialization 
Symeonidou 
et. al.,2017 
How Intellectual property based commer-
cialization strategies allow new ventures 
to increase their international sales at a 
lower cost, due to the less need of having 
units abroad to perform tasks in different 
locations compared to the product based 
and hybrid strategies. 
The emphasis is on building and leverag-
ing network relationships to access and 
mobilize external resources in foreign 
markets. 
Chiesa and 
Frattini, 
2011  
How commercialization decisions (i.e., 
timing, targeting and positioning, inter-
firm relationships, product configuration, 
distribution, advertising, and pricing) can 
determine lack of support from the inno-
vation’s adoption network for systemic in-
novations and a negative post-purchase 
attitude of early adopters for radical inno-
vations. Focus is on the actions that 
should be taken for improving the out-
come of commercialization activities. 
When commercializing innovations, fo-
cus should be on: 1) Positioning the 
product clearly and as a revolutionary 
technology instead of a product line of a 
successful brand to prevent early 
adopters from perceiving it as a 
downscaled version. 2) Avoiding the 
early preannouncement if the product 
configuration is not yet ready for launch. 
3) Functionality of the product so that it 
can fulfill the commitments. 4) Forming 
long-term relationships with the net-
work players that would have an impact 
on product diffusion. 
Öberg & 
Shih,2014 
Similar or different priorities, interests, 
and interactional goals (logic) of the com-
panies in a network affect the develop-
ment of the innovation and commerciali-
zation processes. Emphasis is on the con-
vergent logic of companies in a network 
for the success of a novel innovation. It is 
proposed that parties need to be part of 
the same shared logic nets (SLN) for the 
innovation to be successfully developed, 
with the aim to overcome the conflicts in 
priorities. 
To come to terms with divergent logic 
that may inhibit firms' ability to 
commercialize innovations, innovative 
firms either need to redefine 
their innovation goals to fit into the ex-
isting logic of others, or need to 
find incentives that talk to the interests, 
priorities, and interaction goals of other 
parties. 
Slater & 
Mohr, 2006 
Focus is on different market strategy 
types to whether choose a prospector ap-
proach and focus on emerging customer 
needs or defender approach and fulfil the 
needs of existing customers 
In order to successfully develop and 
commercialize disruptive innovations, 
not only does the firm need to concep-
tualize and develop the innovation in 
the first place; it must also be successful 
in reaching more than just a niche mar-
ket of innovators–early adopters. In 
other words, it must overcome the inno-
vator’s dilemma as well as cross the 
chasm. 
Perks & 
Moxey, 2011 
How task partitioning and resource shar-
ing practices, and their evolution over 
time are related to the nature and scope 
of capabilities of lead firms within the con-
text of market-facing innovation net-
works. 
A relational approach distributes innova-
tion and commercialization capability 
around the network. It can enable com-
panies to rely on external partners to ac-
cess resources and capabilities, and also 
can boost the innovativeness of these 
partners. 
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Aarikka-
Stenroos & 
Lehtimäki, 
2014 
A dynamic process model for the commer-
cialization of radical innovations and the 
challenges a firm face when probing its 
way to the market and how to cope with 
these challenges 
Commercialization process involves con-
tinuous experimenting and iterative 
probing between strategic zone, market 
creation and preparation zone, and sales 
creation and development zone. The im-
portance of market creation and prepa-
ration zone shouldn’t be ignored.  
Kern (2001) remarks that companies commit to different activities with the intention to 
increase their monetary wealth. Firms allocate their resources to perform activities to meet 
their various interests and priorities. The question of what activities are performed and 
how they are performed can be asked. The decisions that determine the activities are made 
based on the combination of resources, competences, interests and priorities (Nielsen & 
Parker, 2012). They state that interests and priorities determine the firm's unique motiva-
tion. The trust and commitment can be observed between the network parties as the in-
teraction develops (Ford, 1980) but still, firm’s motivations will be the main element that 
have a role on the interaction goals (Öberg & Shih, 2014).  
In a network, firms tend to pursue their own interests and goals instead of performing 
activities that benefits the whole network (Corsaro & Snehota, 2011), which inhibits the 
collaboration, as the motives of venture firms and investors might be conflicting (Masulis 
and Nahata, 2011). It is expected that companies might differ in terms of the goals and 
directions, but in some cases there is a need to cooperate in certain capacities (Wilkinson 
et al., 2005). They point out that, partner selection is affected by the close relationship of 
the parties, which has an impact on having the similar goals, interests and priorities. How-
ever, Corsaro and Snehota (2011) state that even though the parties may have a match 
regarding resource needs, if they employ different logics, relationships may fail.  
Chiesa & Frattini (2011) point out that in radical innovations, the right positioning strat-
egy determines the effectiveness of communicating the product value and product’s use areas to provide a clear understanding on how the product actually benefits the customers. 
Positioning the product as a revolutionary innovation that is different from its competitors 
is more effective than declaring the product as a continuation of a product line of a well-
known brand. Special efforts should put on fully completing the product development to 
make the product configuration ready for launch, as well as the consistent, not contradic-
tory preannouncement of the product features and avoiding announcing the features that 
are not finalized, which are the main aspects for early adopters to purchase the product. 
As the preannouncements are used to communicate with customers to increase the speed 
of the diffusion and draw customer interest (Eliashberg and Robertson, 1988), a con-
sistent, reasonable and honest information flow is needed.   
The literature on commercialization of innovations shows that two types of variables de-
termine the market success or failure, which are strategic and tactical variables (Hultink 
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et. al., 2000). The strategic decisions are assessed and made prior to the start of the de-
velopment, while tactical decisions comprise the marketing mix (product, price, place, 
promotion), and are considered during the development (Chiesa & Frattini, 2011). These 
variables are listed in the table below. For each variable, an example of an activity is 
given that helps the achievement of market success of the innovation with the aim of 
receiving positive response from the early adopters and the extensive support from the 
adoption network depending on the type of the innovation. Table 4 below is created based 
on the research in radical and systemic innovations in high-tech industries (Chiesa & 
Frattini, 2011). 
Table 4. Variables that affect commercialization decisions (Adapted from Chiesa & Frattini, 2011). 
Type of 
Variable 
Variable Activity  
Innova-
tion Type 
Strategic 
Timing 
 Timing of the innovation's preannouncement 
and launch should be well planned and the gap 
between shouldn't be too long 
Radical 
 Long-term partnerships should be formed prior 
to the diffusion in the market 
Systemic 
Targeting and 
Positioning 
 Positioning of the innovation as a revolutionary 
technology 
Radical 
 Targeting the new product at any specific seg-
ment immediately after launch 
Radical 
 Configuring and positioning the product in a way 
that meets early adopters’ expectations 
Radical 
Inter-firm Rela-
tionships 
 Establishing relationships with critical players in 
network 
Systemic 
 Licensing of technology to complementary prod-
uct developers for a low price or for free 
Systemic 
Tactical 
Product 
 Product functionalities should address the expec-
tations of early adopters 
Radical 
 The complete set of product functions should ex-
ist as it is presented at the preannouncement 
campaign and work properly at the time of the 
launch  
Radical 
 Use of the product should be simple and easy to 
understand. It shouldn't contain complex func-
tionalities 
Radical 
Advertising and 
Promotion 
 Focus on preannouncement campaign should be 
on product's technical capabilities instead of pro-
moting it as the continuation of the product line 
of a successful brand 
Radical 
 Product configuration at launch and at the pre-
announcement campaign should be consistent 
Radical 
Pricing and Dis-
tribution 
 Late adopters may find pricing and distribution 
channels critical, as these factors are not a con-
cern to early adopters and the adoption network 
Both 
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The success of a commercialization decision of new innovation is highly dependent on 
the customer acceptance, financial performance, technical and functional performance of 
the product and contribution to the firm’s competence base (Cooper and Kleinschmidt, 
1987; Griffin and Page, 1993). Therefore, planning of activities should be made, taking 
into account the customers purchase behavior, their expectations and needs, products 
technical capabilities and its readiness level for product launch, information consistency 
of preannouncement campaigns, and the importance of building relationships with critical 
partners. Timing of setting up the relationships is essential in a commercialization pro-
cess. It is suggested that the companies should start building up relationships in advance 
and constantly ask feedbacks, work with partners and share resources (Perks & Moxey, 
2011). 
According to Rogers (1995), customer segments split into five types in diffusion of inno-
vations, which are innovators, early adopters, early majority, late majority, and laggards. 
For an innovation to be successful, adoption and diffusion from one category to another 
are needed. Each of these adopters have different buying needs and thus innovator firms 
need to find ways to disseminate innovation throughout the segments. As the diffusion 
starts with innovators and lead users, which is also one stakeholder group that influence 
the commercialization of an innovation, their contribution and adoption has the highest 
effect on the following chain reaction of adoptions from the next segments. Innovators 
are the initiators of the mass adoption of an innovation throughout the markets. As the 
segments start to use the innovation and the shifts become more obvious from one seg-
ment to another along the process, the commercialization efforts on the innovation should 
be increased. Bell-shaped curve of the diffusion of an innovation is illustrated in Figure 
1 below. 
 
Figure 1. Customer segments in diffusion of innovations (Rogers,1995). 
Innovators are the technology enthusiasts who are aware of the latest technologies that 
want to use it promptly. They are not price sensitive and they are capable of developing 
solutions to a problem that might occur in an innovation that is recently launched in the 
market. Next, early adopters are also aware of the technologies, but they are not as com-
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petent as innovators. They intend to find new use areas and confirm the usability of tech-
nology. After these two segments, a chasm area forms. According to Moore (1991), this 
area exists because the marketing strategies that firms use to reach the early market for 
technology innovations do not address the different needs of the mainstream market. 
Next, early majority crowds can be seen which are not technologically aware. They want 
ease of use and solutions that meet their needs. Price sensitivity also comes in with this 
group of customers. Next, in late majority category, market becomes more price sensitive 
and more simplistic solutions are needed. The last category is laggards who compare eve-
rything in the market and want the cheapest solution of a need.  
As mentioned before, chasm area is between the early adopters and the early majority. 
The area that corresponds to the innovators and early adopters segments before chasm 
represents the customers who are more technologically oriented. Once the innovation 
penetrates through the mass markets after chasm, the emphasis and activities should be 
more on the marketing and pricing side instead of the technological features of the inno-
vation (Rogers, 1995). Many companies miss this distinction of chasm that divides the 
customers into two simple categories who wants new technologies and the customers who 
wants to fulfil their needs. 
Slater & Mohr (2006) argues that company’s capability to successfully commercialize a 
disruptive innovation depends on its selection of the target market and how well the com-
pany modifies its initial marketing approach to address the mainstream market, as well as 
their strategic orientation to whether focus on existing customer needs (sustaining inno-
vations) or emerging customer needs (disruptive innovations). Miles and Snow (1978) 
state that companies may choose one of the following strategies to approach their product-
market domains. Prospectors focus on exploiting new products and market opportunities 
that help disruptive innovations diffuse in market. Defenders pursue addressing a partic-
ular portion of the market to create a stable set of products and customers, which helps 
sustaining innovations to have a strong position in the market. Lastly, analyzers both seek 
new products and markets, and also maintain a stable set of products and customers. Pro-
spectors more likely get positive results by targeting the innovator and early adopter seg-
ments, whereas for analyzers these results are obtained by targeting the early adopters 
and early majority segments, which makes prospectors more capable of developing dis-
ruptive innovations.  
According to Slater & Mohr (2006), market-share leaders tend to be analyzers and de-
fenders because those strategy types target the early and late-majority segments of the 
market comprising approximately two-thirds of market demand. They suggest that com-
panies should develop skill sets of each strategy type and need more proactive approach 
to developing customer knowledge to address the needs of broader range of customer 
segments. Prospectors should develop some of capabilities of analyzers and defenders 
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and vice versa. Different findings from various researchers (Slater and Olson, 2001) re-
mark that different strategy types have different resources and capabilities for targeting 
different market segments.  
Christensen and Bower (1996) point out that the companies that focus too much on their 
existing customers are not capable of coming up with a disruptive innovation and they 
lose their industry leadership position, due to the missed opportunities that new markets 
and customers might bring. In one of Christensen’s research (1997), it is said that a new 
technological innovation introduces new features, performance, and price attributes, 
which may have a higher customer perceived value relative to the existing technology 
and cause the discontinuity of existing technology. He also argues that because of listen-
ing too carefully to the customers, companies are disrupted by industry newcomers that 
address emerging customers. Additionally, the study of Govindarajan and Kopalle (2004) 
showed that, focusing on emerging customer segments rather than mainstream customers 
provided a higher capability of developing disruptive innovations. Slater & Mohr (2006) 
point out that customers do not know or are not aware what they want until some tech-
nology provider manufactures and shows the innovation to them. Until the point they see 
the innovation, they are not dissatisfied either, because they were not aware of that need.  
This is also one of the examples of how emerging customer segments appear. Innovator 
companies should speculate what the potential customers may be in need in the future 
and come up with a revolutionary technological innovation that customers would value.  
According to Slater & Mohr (2006), customer-visit programs, empathic design, lead-user 
research, end-user (customers of customers) research, and targeting developing markets 
are the sources of new information that may have influence developing new innovations.  
2.3 Commercializing a Functional Food Innovation 
In this chapter, management and marketing approaches, challenges in innovation activi-
ties and positioning, consumers’ perception about functional foods, actors that influenced 
the progress of innovations in functional food industry, which correlate with the case 
study of the thesis are discussed. As the functional foods became popular in the end of 
1990’s and the term ‘functional’ became a buzzword that has been used by many food 
producers on their products without any specific scientific study that backs up the func-
tionality claim, the need arised for regulating the claims made by food producers 
(Granqvist & Ritvala, 2016). Strict rules and regulations were applied, which was needed 
to ensure the safety of the food products that carries no risks on health. However, this 
brought difficulties to innovator companies for entering to a new market category. Com-
panies needed to put more efforts and resources to obtain the right to put the health claim 
labels on their products, which resulted in relatively delayed product launches in various 
markets. Regarding the health claims on food products, one important thing to point out 
is that in a survey carried out by Mintel in 1999, it was seen that 77% of 922 adults that 
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were surveyed believe that health claims made by food manufacturers about their prod-
ucts are misleading. For widely recognized health positioning, this brings up the question 
whether companies that want to enter to the market should put more efforts on the health 
claims or on the skillful communication campaigns to raise consumer awareness of prod-
uct benefits.  
In food and drink industry, historical studies (Earnst & Young and Nielsen, 1999) showed 
that innovative products accounted for only 1.4% of the new product activity that was 
launched in a 13 month period in the countries the study took place, while the copied 
products accounted for 76.7% of the new product launches, which had a huge failure rate. 
The innovation activities apparently are much lower in food and drink than in other in-
dustries. Mellentin and Heasman (2001) argue that this is due to the fact that food and 
drink industry has a low-tech business environment, takes a longer time for a product to 
be profitable if succeeds, and differentiation of the products are difficult to achieve be-
cause they are easily imitable by competitors. The previous study (Grunert, 1998) showed 
that the ratio of the innovation activities over new product activities in electronics, phar-
maceutical, and food industries is the lowest in food industry, which can be seen in Table 
5 below. 
Table 5. Innovation activity over new product activity ratios in 3 industries (Grunert, 1998). 
  Electronics Pharmaceutical Food 
Denmark 12.7 18.0 1.2 
France n/a 31.7 1.6 
Germany 15.6 16.0 1.2 
Japan 18.4 13.0 2.0 
Sweden 33.2 41.2 1.8 
UK 22.9 22.6 1.0  
Since the overall view of the innovation activities in food industry is dramatically low, 
functional foods provide a new market category which would increase the innovation 
activities of the companies and might give strength to a relatively low tech industry. Busi-
nesses that want to succeed in this market will have to find new ways of management 
practices, particularly in identifying critical technologies (Mark-Herbert, 2004). It is 
pointed out that companies should come up with a strategy that combines market pull and 
technology push, and 3 crucial requirements are underlined to advance in functional food 
industry, which is illustrated in Figure 2 below. To some extent, Benecol acted as a spear-
head and a leading example of an innovation in the functional food industry with its pa-
tented ingredient and scientific research.  
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Figure 2. Requirements to advance in functional foods industry (Adapted from Mark-Herbert, 2004). 
One challenge in commercializing functional food is the recent consumer shift to the or-
ganic products. The positioning of the organic products done by natural food companies 
has been attracting consumers more than the functional foods in general. In an observation 
made by Mellentin and Heasman, it was pointed out that while mainstream food compa-
nies are focusing more on the health improving and curing aspects of the products, the 
natural food companies has taken over and changed the mindset of the consumers to shift 
to the organic food products. Organic products has been perceived as healthier option in 
contrast to functional foods that is packaged and mass marketed (Mellentin and Heasman, 
2001). 
For systematic and effective diffusion of functional foods, scientists played a key role on 
the processes. They were the ones who convinced the top management to invest in the 
new market category (Granqvist & Ritvala, 2016). In particular, the scientific contribu-
tions from Helena Gylling and Tatu Miettinen led to the discovery of positive health ef-
fects of plant stanols on cholesterol reducing effects and played an important role on Ben-
ecol’s awareness creation around the world. Their scientific studies also helped Benecol 
to obtain the right to use the necessary health claims from regulators to reach consumers 
in various markets. 
There are several strategies and marketing approaches that companies can choose when 
commercializing functional foods. Choices should be made on particular points and the 
success of the selected strategy depends on the market condition, product type and how 
consumers perceive the products. In all these situations, consumer communication is es-
sential to build an image of functional foods. These strategies include applying a regular 
pricing or premium pricing, cannibalization of the other products in the product range or 
incremental business, targeting the mass market or niche, targeting a disease healing fea-
ture or well-being, and launching the product with a health claim or without (Mellentin 
and Heasman, 2001). 
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2.4 Multi-Actor Approach in Commercialization 
In order to better understand how the commercialization activities advance over time, a 
multi actor approach is evaluated and the impacts of different stakeholders around the 
innovator firm that influences the commercialization process are assessed. A successful 
commercialization of an innovation requires collaboration among several actors 
(Aarikka-Stenroos, Sandberg, & Lehtimäki, 2014). Partners with complementary types 
of scientific and practical competences must work together in the commercialization ac-
tivities from beginning to end. Therefore, the relationship between these multiple actors 
are studied and assessed. In Table 6 below, three common multi-actor approaches in com-
mercialization and their research focus are explained.  
Table 6. Multi-actor approaches in commercialization. 
  Stakeholder Approach Network Approach Ecosystem approach 
Author,Year 
Driessen & Hillebrand, 
2013; Talke & Hultink, 
2010; Freeman, 1984 
Öberg & Shih, 2014; Symeonidou 
et. al.,2017; Denk et al., 2012; 
Musteen et al., 2014; Coviello, 
2006; Perks & Moxey, 2011; Law, 
1992; Aarikka-Stenroos & Lehti-
mäki, 2014 
Chiesa and Frattini, 
2011; Moore, 1996; 
Iansiti & Levien, 2004 
Research 
Focus 
Focus is on managing 
and involving all the 
stakeholders, relation-
ships and their inter-
ests for ensuring the 
long-term success of 
the focal firm, its 
stakeholder integration 
capability, and the 
achievement of its ob-
jectives. 
Emphasis is on building and lever-
aging network relationships to ac-
cess and mobilize external re-
sources to gain a competitive posi-
tion in markets. Task partitioning 
and resource sharing in market-
facing innovation networks are of 
importance. Shared logic nets 
(SLN) and convergent logic of 
companies in a network affects 
success of a novel innovation, with 
the aim to overcome the conflicts 
in priorities.  
Focus is on interaction 
of customers, distribu-
tors, legislators, ex-
perts, and comple-
mentary products that 
develops a firm's un-
derstanding of the 
benefits for adoption 
from the customers' 
and stakeholders' per-
spective. 
Approach in 
Managing 
Actors 
Using stakeholder is-
sue identification tech-
niques, coordination 
mechanisms, and pri-
oritization principles 
for developing a capa-
bility for stakeholder 
integration. Addressing 
non market stake-
holder issues with re-
gards to the environ-
mental impacts and 
keeping these green is-
sues on the agenda. 
To come to terms with divergent 
logic that may inhibit firms' ability 
to commercialize innovations, in-
novative firms either need to re-
define their innovation goals to fit 
into the existing logic of others, or 
need to find incentives that talk to 
the interests, priorities, and inter-
action goals of other parties. An 
actor in a central position in the 
network can orchestrate other ac-
tors towards a goal. 
Educating customers, 
creating an active sup-
portive network of di-
vergent stakeholders, 
scaling up production 
and distribution net-
works, integrating the 
innovation into the 
mainstream business 
and production set-
ting, inspiring the 
whole value chain and 
complementary mar-
ket actors. 
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Stakeholder approach suggests that managers need to come up with processes which ben-
efit all and only those groups who have a stake in the business. The main point of the 
process is to manage and involve all the stakeholders, relationships and their interests for 
ensuring the long-term success of the firm and the achievement of the organization’s ob-
jectives. This approach requires active management of the business environment, rela-
tionships and the promotion of shared interests (Freeman & McVea, 2001). Stakeholder 
concept is used in multi-contextual applications, and it is subject to many different inter-
pretations depending on the attributes of the context (Miles, 2017). According to Stoney 
and Winstanley (2001), the multitude of conflicting views caused substantial confusion. 
Failure to recognize and map this diversity of definitions and views weakened the stake-
holder concept. Many scholars (Crane and Ruebottom, 2011; Fassin, 2009; Sternberg, 
1997) argue that the definition of the concept is ambiguous, confusing, and contested. 
Improper use of the term might cause it to become another buzzword in literature. Sachs 
and Maurer (2009) point out that stakeholder-organization relationships can be analyzed 
from the management point of view, the stakeholder or both. For a stakeholder to be rec-
ognized, there must be a stake, right, or interest (Miles, 2017).  
Stakeholder approach aims to study the interests and goals of the organizations in partic-
ipating in the commercialization activities from the integrated stakeholder perspective, 
having a stake in the relationships. Rather than separate strategy for every stakeholder, 
managers must find ways to satisfy multiple stakeholders simultaneously (Freeman & 
McVea, 2001). Luoma-aho and Paloviita (2010) argue that the environment in which cor-
porations operate today do not only consist of human interactions, but also different tech-
nologies, infrastructures, and political agendas. It is argued that these non-human entities 
can be also considered as stakeholders, which can turn unexpected individuals or groups 
into important stakeholders. According to Phillips, Freeman, and Wicks (2003), stake-
holder theory addresses morals and values explicitly. Apart from maximizing shareholder 
wealth, managing for stakeholders implies attention to several things. They state that in-
terests and well-being of those who can assist or hinder the achievement of the organiza-
tion's objectives are critical. They point out that in this way, stakeholder theory is similar 
in large degree with alternative models of strategic management such as resource depend-
ence theory. 
Network approach challenges stakeholder theory to include all the different elements of 
society that are linked. Constant support from every member of the network is a necessity 
accordingly. This approach connects the whole network chain actors such as regulators, 
manufacturers, universities, customers, provides a full interaction and creates an exten-
sive dynamic setting. Network approach differs from stakeholder approach by shifting 
from corporation-centered approach to the various networks in operation in society. It 
emphasizes the importance of the activity in the operating environment and actively mon-
itoring this environment. Issues management is also of concern in network approach, as 
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many of the networks are formed around issues, not the corporation or stakeholders. Cor-
porate communications are essential for keeping people involved, achieving a community 
mindset and avoiding corporate crises in network approach (Luoma-aho and Paloviita, 
2010). It is stated that actor-network theory is a relational and process-oriented sociology 
that treats agents, organizations, and devices as interactive entities. It suggests to treat 
different materials such as people, machines, ideas as interactional entities rather than 
primitive causes, and the social effects of each should be explored in this approach (Law, 
1992). 
Business ecosystem is an economic community supported by a foundation of interacting 
organizations and individuals, and it is based on core capabilities, which are exploited in 
order to produce the core product (Moore, 1996). Promoting the health and the stability 
of a firm’s ecosystem depends on the firm’s role within the network. Developing a strat-
egy to be a niche player, a keystone, or a dominator determines the firm’s position in the 
ecosystem and ensures the firm’s well-being. Most companies today exist in ecosystems 
that consists of networks of suppliers, distributors, technology providers and other organ-
izations that affect, and are affected by the creation and delivery of a company's own 
offering. The actions that a company take in an ecosystem eventually affect its business 
network, which result in changes in the organization's performance. Therefore, firms must 
pursue strategies that will benefit everyone in the network, as their fate depends on each 
other’s activities. It is stated that the health of the ecosystem suffers when a specific busi-
ness utilizes more value than it creates. The role of the organization might change as the 
ecosystem changes, thus understanding the ecosystem and planning the next strategic 
moves to select the business partners for long-term success is essential (Iansiti & Levien, 
2004). Peltoniemi and Vuori (2004) state that in business ecosystems, there is both com-
petition and cooperation. 
As a conclusion, the focus on one individual party increases as the approach moves from 
ecosystem to network approach, and from network to stakeholder approach. In stake-
holder approach, the focus is more on managing the stakeholders for the long-term suc-
cess of the focal firm, while in network approach the focus is on leveraging network re-
lationships to access and mobilize external resources. In ecosystem approach, the aim is 
to improve the well-being and the current state of the ecosystem members in a broad 
context. Every member of the network cooperates for the benefit of the ecosystem they 
are involved in. The balance between value creation and value utilization in an ecosystem 
should be well managed to keep the members of the ecosystem motivated and to maintain 
the core competences. 
In the next chapter, the definitions of different types of stakeholders, the broad network 
of actors, and their relation between each other will be discussed. 
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2.5 Stakeholders in New Product Development 
Stakeholders are defined as any group or individual who can affect or is affected by the 
achievement of the organization’s objectives (Freeman, 1984). The stake that stakehold-
ers have is that they stand to gain or lose something from the organization’s success 
(Driessen & Hillebrand, 2013). They point out that to process the market information 
about stakeholders, external environment can be utilized. This information then can be 
used to improve stakeholder theory by considering how information is integrated in new 
product development. Stakeholder theory emphasizes the importance of the environment 
along with shareholders. Greenley and Foxall (1998) clarifies that organizations that have 
more information about the stakeholders in the environment have higher organizational 
performance. According to Miles (2017), stakeholder concept is a contested concept in 
practice and it is open to many different interpretations. It is possible to generate many 
definitions depending on the ideology and social positioning of the person who defines 
the term. 
Stakeholder theory describes defining the relevant stakeholders of a company and the 
conditions in which managers consider these parties as stakeholders (Phillips, 2003). It 
also considers the stakeholder integration in organization’s decision processes (Hart, 
1995). Stakeholders are defined as employees, the mass of users and customers (lead us-
ers, boundary spanners, opinion leaders, communities), suppliers, manufacturers, media, 
universities, public organizations, expert organizations, investors, financiers, competi-
tors, communities, policy makers, regulators, governmental bodies, political groups, trade 
associations, trade unions, and complementaries (Aarikka-Stenroos, Sandberg, & 
Lehtimäki, 2014; Miles, 2011). Diverse actors with their main and individual contribu-
tions to the commercialization process are illustrated in Figure 3 below. 
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Figure 3. Diverse actors grouped by main and individual contributions to commer-cialization (Adapted from Aarikka-Stenroos et. al., 2014). 
Aarikka-Stenroos et. al. (2014) indicate that stakeholders make three types of main 
contributions to commercialization processes, which are creating markets for innovations, 
facilitating and accelerating further adoption, and lastly, performing practical 
commercialization tasks. Activities for creating markets for innovations do not directly 
support a product or organization, but strengthens the market conditions and build the 
base and environment for innovations to diffuse easier. Some actors that perform 
activities for market creation are regulators, investors, media, public organizations, 
suppliers and manufacturers. Activities for facilitating and accelerating further adoption 
includes influencing the attitudes and choices of the critical mass. These tasks are done 
by universities, media, users, suppliers, distributors and other complementary 
organizations. And the last contribution to commercialization process, which is 
performing practical commercialization tasks, is vital for the innovator company and it is 
done by distributors, users, media, investors, and other organizations. Commercialization 
tasks involve spreading information about the benefits of the innovation, delivering 
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innovations and enabling its distrubution to the users, and providing monetary resources. 
As the activities move forward from creating markets to facilitating adoption, and from 
facilitating adoption to performing commercialization tasks, the contribution of the 
stakeholders shifts gradually from indirect to direct, and from unintentional to intentional. 
Some of the indirect contributors can be considered as associations, public organizations, 
expert opinion leaders, and regulators, whereas the direct contributors are described as 
distributors, complementaries and investors (Aarikka-Stenroos et. al., 2014). 
Every stakeholder have contribution in the commercialization process. Consumers and 
users support the communication of the innovation among the user networks, spread 
word-of-mouth, demonstrate the use cases, give feedback on market structure and product 
quality, present benefits and act as a critical mass of adopters (Perks and Moxey, 2011). 
Lead users are ahead of the mass market and speed up the information flow. They assess 
if the product features meet the user needs and they propose adjustments. Communities 
of users create public awareness by organizing conferences, seminars and discussions. 
They also assess the product features to acknowledge that it meets the end user 
requirements (Hienerth and Lettl, 2011). Distributors make the innovation available to 
users by delivering them (Perks and Moxey, 2011). Suppliers and manufacturers 
implement applications and use licensing to increase the usage. Expert organizations 
consist of designers, engineers, and consultants, which increase organizat ional learning 
on commercialization (Story et al., 2009). Complementaries promote the use of the 
innovation by developing new business fields, and requiring their clients to use the 
innovation. Partnerships with complementaries increase the reputation and credibility of 
innovator company and make it easier to reach higher number of customers due to the 
higher size of the installed base and the variety of complementary products (Perks and 
Moxey, 2011). Granqvist and Ritvala (2016) remark that public funding agencies act as 
important market makers that often have a major incentive to establish growth in a market 
category. Investors help innovators to find companies seeking to fund. Pontikes (2012) 
states that venture capitals and firms that introduce novel offerings create new markets 
and new niches. Public organizations and non-profit organizations promote the use of the 
innovation in society and build relations with governmental bodies. Trade and profes-
sional associations disseminate information and build trust for the innovator company. 
Members of these associations are from different sectors, thus they can help to weaken 
the negative biased perceptions about the innovation (Aarikka-Stenroos and Sandberg, 
2012). Universities and academics build trust by researching and acknowledging the ben-
efits with scientific proof (Bercovitz and Feldman, 2011). Policy makers, regulators or 
governmental bodies shape the standards that affect commercialization. Policy makers 
provide financial resources by funding individual projects. These institutions play an im-
portant role on networking of actors and help them start new collaborations to strengthen 
the clusters (Story et al., 2009), which are geographic concentrations of interconnected 
companies in a particular field (Porter, 1990). The media builds awareness by delivering 
the latest updates and developments about the innovation and the company to the audience 
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(Aarikka-Stenroos and Sandberg, 2012). Lastly, all players of the industry and collabora-
tion between them form the industry structures and create push and pull mechanisms of 
markets (Chiesa and Frattini, 2011). 
According to Granqvist and Ritvala (2016), although previous research in market catego-
rization showed that prototypical similarity is the main driver of categorization, it misses 
to remark the importance of evolving perceptions, goals, and knowledge of the network 
actors, which have a role in determining categorization. Their longitudinal case study in 
market categories of functional foods and nanotechnology in Finland revealed that goal-
based categorization is vital for the permanence of the categories in the market, rather 
than the causal-based categorization. They point out that dynamic market categories are 
continuously changing over time naturally, and apart from prototypical similarity, actors’ 
goals and interests have an impact on that change. It is also stated that the similarity of 
technology, resources and customers, are the only drivers of market categorization (Hsu, 
2006; McKendrick et al., 2003). In functional food category, scientists were the major 
actors that contributed to the creation of that particular category by influencing the regu-
lators and spreading knowledge in the environment. Over the years, the requirement of 
causal relationship between the consumption of a functional food and the claimed health 
benefit diminished the possibilities for goal-based activities. Regulators applied strict 
rules that limited the potential for goals-driven participation, which led to the mature pe-
riod in that market category. Since the statistical methods used in research of a functional 
food were the first ones of its kind, the regulators were not familiar with it and they in-
validated the research, which caused the innovator company to be not legally permitted 
to use a health claim (Granqvist and Ritvala, 2016). Regulators require a link between a 
product and a positive health effect of that product, which is a causal-based model, and 
they consider that as a reference for category assessment and boundary drawing. These 
examples show that in functional foods, strict rules and regulations inhibited the growth 
of the market category, and discouraged the new entrants for entering the market. 
It is emphasized that commercialization network indicates innovators' perspective, while 
adoption network indicates other stakeholders' perspective. It is also stated that for radical 
innovations, the support from diverse actors for research and development is essential as 
the decisions affect many interrelated actors. The organizations that develop radical in-
novations should also have advanced networking capabilities, as the networks are more 
likely created, abandoned, and reformed quicker in radical innovations than in incremen-
tal innovations. Aarikka-Stenroos and Sandberg (2012) state that when trying to get sup-
port from prospective contributors, small firms may face obstacles due to their relatively 
lower size and novelty. This is an important issue for small innovator companies as the 
actors surrounding them would convey knowledge and resources that facilitates commer-
cialization, and these actors are often interconnected with each other, which creates an 
interactive dynamic network.   
24 
Market and non-market stakeholders are players that have an impact on the management 
decisions in new product development. Market stakeholders are considered to be the ones 
that are directly involved in the product market and have a role on an exchange, which 
are customers, competitors, suppliers, and retailers. Non-market stakeholders are the ones 
that are not directly involved in that type of an exchange, which are regulators, employ-
ees, and special interest groups (SIG) such as Greenpeace (Driessen & Hillebrand, 2013). 
Donaldson and Preston (1995) state that managers are type of a stakeholder, but these 
managers’ responsibility also includes determining other stakeholders that are related to 
the company.  
In the study that Driessen & Hillebrand (2013) conducted, multiple stakeholder issues in 
new product development were brought up. In that study, they stated that there are several 
stakeholder issue identification methods that an organization can use, which helps 
organizations to also identify the issues of the non-market stakeholders. As they are the 
ones that brings environmental issues forward, focusing on and identifying non-market 
stakeholder issues tend to bring green issues into the NPD process that often conflict with 
other stakeholder issues, which creates tensions. The issues of non-market stakeholders 
matter, since they are related to the environmental aspects of the processes or production, 
which are not the main concerns of the market stakeholders. Nonmarket stakeholders are, 
increasingly so, part of the environment in which NPD teams operate, and need to be 
considered in NPD decisions. Therefore, it can be said that addressing nonmarket 
stakeholder issues means the coordination and prioritization of green issues, which are 
the main reason of the tensions that occurs between stakeholders (Driessen & Hillebrand, 
2013). 
Some examples of structured techniques to identify nonmarket stakeholder issues are 
setting up international monitoring system to observe regulatory updates and continuous 
dialogue with SIGs to understand the environmental impacts of activities. After 
identifying the issues, comprehensive stakeholder management system and various 
guidelines, norms, and procedures can be used, concerning the inclusion of green issues 
in the NPD decision-making process. In order to manage the tension between 
stakeholders, coordination mechanisms are used, which range from formal to informal. 
Formal ones are the written instructions to include green practices, whereas informal ones 
are the regular discussions in NPD meetings. These mechanisms are established to not to 
skip green issues in NPD project discussions and including them in firm’s agenda. Later, 
to ensure that green issues are one of the main concerns, several prioritization principles 
can be employed to assess green issues with other issues (Driessen & Hillebrand, 2013). 
Consequently, to develop a capability for stakeholder integration, three components are 
essential: stakeholder issue identification techniques, coordination mechanisms, and 
prioritization principles (Leonard-Barton, 1992). Driessen & Hillebrand (2013) remark 
that higher proactivity of environmental management and environmental impact of the 
industry may affect the development of stakeholder integration capability positively. This 
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capability increases organizational identification and may result in stakeholder resources, 
which means helping the organization by sharing knowledge or buying its products 
(Maignan and Ferrell, 2004). 
As diverse stakeholders are involved in innovating, it complicates interaction by 
increasing a mismatch in actors’ goals, which leads to conflicts and uncertainty (Aarikka- 
Stenroos & Sandberg, 2012). Firms can mobilize or influence other actors through 
relationships to achieve their goals (Mouzas & Naudé, 2007). Research has showed that 
radical innovations induce new markets and relationships, thus changing the network 
structure, compared to incremental innovations (Aarikka-Stenroos et. al., 2017), which 
means radical innovations require network visioning whereas incremental innovations 
require involvement of network actors. Recognition of these actors' interests when 
inducing changes in the network is essential for managing the network (Medlin, 2004). 
Eventually, networks can help companies to eliminate challenges they might face 
throughout the commercialization process of an innovation. Next chapter will discuss the 
network aspect in more detail and provide an overview of the importance of the mutual 
goals, interests and priorities among these network actors for an innovation to be 
successful. 
2.6 Business Networks in Commercialization 
Previous study (Aarikka- Stenroos & Sandberg, 2012) showed that networks can offer 
complementary resources to support commercialization activities of innovations and pro-
vide the required environment for an innovation to diffuse. They state that, utilizing net-
works might provide cost savings to the small innovator companies which lack resources 
to reach customers, and interaction between these network players are important particu-
larly in the functional food industry (Matthyssens et al. 2008). Additionally, networking 
capability and gaining the trust of the organizations of a network are critical for innovator 
firms for resource expansion to reach out customers easily. 
Business networks refer to interconnected firms that share activities and resources among 
themselves (Axelsson & Easton, 1992). These networks consist of customers, suppliers, 
distributors, media, universities, public organizations, expert organizations, investors, 
lead users, and regulators. Companies that participates in innovat ion networks have dif-
ferent motives for engagement or contrarily, for not taking part and interacting (Corsaro 
& Snehota, 2011). These motives are related to the business goals of the companies and 
it concerns the company’s reasons to interact with other firms in the innovation process 
(Öberg & Shih, 2014). They state that, the interests, priorities and interaction goals of the 
participating companies of a network are of importance, regarding development and com-
mercialization activities. They define the terms as following in Table 7 below: 
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Table 7. Definitions of priorities, interests, and interaction goals. 
According to Öberg & Shih (2014), similar or different priorities, interests, and interac-
tional goals (logic) of the companies in a network affect the development of the innova-
tion and commercialization processes. They emphasize the convergent logic of compa-
nies in a network for the success of a novel innovation. It is proposed that for the innova-
tion to be successfully developed, network parties would need to be part of the same 
shared logic nets (SLN), with the aim to overcome the possible conflicts in priorities of 
companies. SLN in a business network considers the connected companies with the same 
convergent logic, rather than the interactions itself. Consequently, companies in a SLN 
that have convergent logic do not necessarily interact with each other, but their logic may 
impact a party (Pick, 1999). For example, policy makers have an impact on the other 
parties regardless of the interaction. Shared logic nets as part of a network is illustrated 
by Öberg & Shih (2014) in Figure 4 below. 
Term Definition (Öberg & Shih, 2014) 
Priorities 
How parties choose between alternatives, and in this context, refer to their ori-
entation toward incremental or radical innovations. 
 
Interests 
Shows intention toward the innovation and identifies whether the parties are 
open to new ideas. 
Interaction 
Goals 
How and why companies choose to interact with other parties in the innovation 
process. 
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 Figure 4.  Shared logic nets in a network (Öberg & Shih, 2014). 
In the Figure 4, dotted lines that create an ellipse represent a shared logic net among 
companies, while straight lines represent the direct interaction between parties. Here, it 
can be seen that although two companies are in the same shared logic net, they do not 
interact with each other. As an example, this interconnection can be between a policy 
maker and a developer or manufacturer. In these shared logic nets, parties with the con-
vergent logic that has same priorities, interests, and interaction goals are clustered and the 
ones with divergent logic is separated. A company in a network that has a divergent logic 
than others might need to reevaluate its priorities and goals for the success of the innova-
tion. These goals and priorities should be in line with the members of the network or some 
reasons and leads should be introduced to other network members to address their goals 
and priorities (Öberg & Shih, 2014). 
In order to emphasize how networks affect the innovation diffusion depending on the 
innovation type, Chiesa & Frattini (2011) state that market failure of a radical innovation 
is affected by the negative post purchase attitude of early adopters, while a systemic in-
novation is affected by lack of support from the adoption network. This result is explained 
by the strong relation between the adoption network support and market performance 
regarding systemic innovations. Systemic innovations tend to fail if there is no support 
from the network actors, as it requires a much deeper change in the current system than 
it requires in radical innovations and needs support from the network. As for radical in-
novations, the market failure is more likely caused by the negative acceptance of early 
adopters. In systemic innovations, expected benefits are easier to foresee and one actor 
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can orchestrate the whole network, whereas in radical innovations goals, resources, and 
activities are unclear and develops over time (Aarikka-Stenroos et. al., 2017). 
When the consumer’s initial expectations of a product do not match with the perceived 
value they receive after the purchase of the product, satisfaction levels diminish (Church-
ill and Surprenant, 1982). With regard to the customer acceptance, according to 
Chakravorti (2004), interdependent players do not switch to a new product unless they 
see that other players are also convinced to shift to use these products, which makes cus-
tomer acceptance even more difficult. Combining with the consumer’s personal assess-
ment of product’s capability to meet their demands, the attitude of network players to-
wards the new product has a significant effect on product’s market success. The players 
in that network that might shape the decision of a switch to the new product might be the 
companies that supply products or services complementary to the innovation, and com-
panies involved in distributing the innovation or information (Chiesa & Frattini, 2011). 
The authors give product examples of Sony MiniDisc and 3DO Interactive to explain the 
market failure of these products due to the lack of search for support from their adoption 
network. According to them, innovator companies should not expect that product diffu-
sion would naturally attract network players to support innovations, and the historical 
data on this matter backs up this statement (Chiesa & Frattini, 2011). They point out that 
initiating long-term partnerships earlier and sharing activities, costs and risks with net-
work partners has proven to be an effective way of promoting products in markets. 
Another example for the importance of obtaining support from the network actors in the 
early phases of the development for the innovation is from Katz and Shapiro (1986, 1992), 
who bring out the “chicken and egg” problem, in which the innovator firm, customers 
and investors enter in a cycle, where all parties in a way anticipate the first move of action 
from the other side. In this dilemma, customers do not purchase the products if they don’t 
see the complementary products or if the product availability is not widespread. Usually, 
this issue concerns the customers that fits into the category of late adopters, as they are 
more interested to see the product value by evaluating the support from its adoption net-
work once the product is diffused successfully (Rogers, 2003). On the other side of the 
problem, companies that would help the diffusion are not willing to invest unless they see 
a solid installed base, which all leads to a cycle that must be broken for the good of inno-
vator firm. This problem can be also explained by an example of a printer company, when 
the company wants to launch new ink cartridges for the printers. To sell high numbers of 
cartridges, many printers should be sold in the first place. However, customers would 
want to see the complementary products for the printers before they make the decision of 
buying. This problem is illustrated in Figure 5 below:  
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Figure 5.  Chicken-egg cycle in business settings. 
This theory emphasizes the importance of obtaining support from the network actors in 
the early phases of the development for the innovation to gain reputation and credibility 
in customer and network settings. In order to receive support from the adoption network 
for a systemic innovation, a company should put effort on improving its inter-firm rela-
tionships. Involving other related network players in the new product development pro-
cesses would enable the innovator company’s products to diffuse in the market, as these 
players would support the innovation and use their resources on producing and commer-
cializing products incorporating the innovation’s current technology (Chiesa & Frattini, 
2011).  
2.7 Stakeholders That Influence the Diffusion of Innovations 
Following the literature reviews on commercialization and stakeholders, a framework is 
depicted below in Figure 6 to present an overview and provide broad understanding on 
how different type of stakeholders play roles on diffusion of innovations and help the 
focal firm in the ecosystem to gain a competitive position. The activities that stakeholders 
perform is not only for their own benefit, but they also contribute to the value creation in 
the ecosystem. These activities are explained along with their motivations: 
30 
 
Figure 6.  Stakeholders around the innovator firm that influence diffusion of innova-tions. 
In the next chapters, research methodology and results of the research will be presented. 
The above framework will work as a basis for the results part as empirical analysis, when 
exploring the activities and motives of stakeholders, as well as the interactions between 
them. Stakeholder activities and motives will be examined in more detail, enabled by 
conducted interviews with several actors. The interviews will be conducted with regula-
tors, a research organization, an opinion leader, a marketing manager of the focal firm, 
licensing partners, and a scientist who had crucial roles on dissemination of the innovation 
in several countries.  
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3. RESEARCH METHODOLOGY 
3.1 Research Design 
This thesis studies how different actors around the innovator firm that comprises an adop-
tion network in functional food industry influence the success/failure of commercializa-
tion of a product. Main research question of the thesis is: 
 RQ: How do different stakeholders influence the success of commercialization of 
an innovation? 
The main research question is divided into four sub-questions as following: 
 Who are the relevant stakeholders that can contribute to commercialization? 
 What kind of activities do stakeholders employ for effective commercialization? 
 What are the motives of stakeholders to be involved in along commercialization? 
 How stakeholders and their activities are interconnected? 
Exploratory research is conducted to gain background information, to define terms, to 
clarify problems and hypotheses, and to establish research priorities. Methods of conduct-
ing exploratory research are secondary data analysis, experience surveys, case analysis, 
focus groups, and projective techniques (Burns and Bush, 2006). In exploratory research, 
researchers are open to new ideas and insights as they proceed. Creativity of the re-
searcher plays a major role in this type of research (Malhotra and Birks, 2000). The nature 
of this thesis is explorative and the goal is to develop the existing theory of commercial-
ization activities, diverse interests and motives of stakeholders by studying the activities 
that different stakeholders employ within an ecosystem in functional food industry. Case 
study method was used to approach the research questions and explore the phenomenon. 
Main research question requires the exploration of the commercialization phenomenon 
and the activities associated with it. Moreover, the need for comprehensive identification 
of the diverse stakeholders and their motives makes this research explorative in nature. 
The research questions in this study are approached with qualitative analysis to explore 
the phenomenon. Qualitative analysis is chosen for this research, because this type of 
analysis leads to spontaneous findings from naturally occurring ordinary events in natural 
settings, and helps the researcher express the findings of the study in a more convincing 
and undeniable way. In contrast to the quantitative analysis, qualitative analysis is orga-
nized into incidents or stories that has a concrete context, which makes it more convincing 
to the reader than plain numbers of quantitative analysis (Miles & Huberman, 1994). Fur-
thermore, the nature of the questions in this research required the analysis to be a quali-
tative one, which seems to be the most appropriate. 
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Qualitative research analyzes data from direct fieldwork observations, in‐depth, open‐
ended interviews, and written documents (Patton, 2005). According to Miles & 
Huberman (1994), qualitative data is usually in the form of words rather than numbers. 
They state that qualitative data is the source of well grounded, rich descriptions of pro-
cesses, and it helps researchers to see the chronological flow of events, to see which 
events led to which consequences, and generate useful theories. Researchers conducting 
qualitative analysis study real-world settings to construct case studies and generate nar-
rative descriptions, which is called naturalistic inquiry and it is the foundation of qualita-
tive research. Inductive analysis takes place in qualitative research. According to Patton 
(2005), qualitative investigations starts with narrative descriptions of notions, then case 
studies of the phenomenon are constructed, and then finally comparisons and interpretive 
search for patterns are made. He states that researchers are able to make firsthand obser-
vations of activities and interactions, and in some cases they can personally engage in 
those activities as participant observer. Researchers can talk with people about their ex-
periences and perceptions, as well as they can conduct formal individual or group inter-
views. Documents and records are examined throughout the process. After collecting the 
notes in the field, researchers can turn this raw data into a more systematic, narrative 
descriptions that are extracted inductively. The purpose of such studies is to gather infor-
mation and generate findings that are useful.  
Flick (2009) explains that in qualitative research, the use of the existing literature is in-
creasingly relevant, and there are several points in the research process where the use of 
the literature can prove helpful or even necessary. He states that in planning research, in 
analyzing materials, and in writing about findings, making use of the existing literature 
about other research, theories, and the methods is essential. In this thesis, to build up the 
literature review, studies from several authors were benefited, whose work are mainly 
about commercialization and stakeholders. The purpose of the literature review was to 
map the relevant actors that take part in commercialization activities of an innovation that 
affect the processes, as well as explaining the broad concept of multi-actor approach in 
commercialization, to give clearer view on the empirical part of the research. 
Case studies are preferred when the researcher has little control over the events and when 
the focus is on real life phenomenon within real life context. Generally, case study method 
is used when “how” and “why” questions are being asked (Yin, 1994). Case studies can 
be used to accomplish various goals such as providing description, testing theory or gen-
erating theory (Eisenhardt, 1989). In case studies as a research method, the case that is 
being studied should be defined, the relevant data to be collected should be determined, 
and what could be done with the data once collected should be planned (Yin, 2003). Case 
studies consist of qualitative data, quantitative data, or both (Yin, 1984). Schramm (1971) 
states that the essence of a case study is that it illuminates a decision on why it was taken, 
how it is implemented, and what is the result. Contextual conditions are covered that is 
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relevant to the phenomenon. Case studies rely on multiple sources of evidence and bene-
fits from prior development of theoretical propositions (Yin, 2003). Stoecker (1991) 
points out that case study consists of the logic of the design, data collection, and data 
analysis all together comprehensively, and it is not only a research design or data collec-
tion feature alone. There are at least five different applications in evaluation research 
(Patton, 1990): 
 Explaining the presumed causal links in real life interventions that are too com-
plex for experimental strategies. 
 Describing an intervention and the real life context in which it  occurred. 
 Illustrating certain topics within an evaluation in descriptive mode. 
 Exploring situations in which the intervention being evaluated has no clear out-
comes. 
 Meta evaluation (A study of an evaluation study) 
The development of case study designs need to maximize four conditions related to de-
sign quality, which are construct validity, internal validity, external validity, and reliabil-
ity (Yin, 2003). According to Patton (1990), in qualitative research, in depth analysis can 
be conducted on small samples. Therefore, qualitative methods are suitable for this re-
search, as the sampling is not great in size and the case company is selected purposefully. 
Patton (1990) states that what constitutes a case or unit of analysis, is determined in design 
stage and becomes the basis for purposeful sampling in qualitative research. In a single 
program case, one may do case studies of several participants, and then cross-case pattern 
analysis of the individual cases might be part of the data. Case studies facilitate a holistic 
understanding of complex phenomena that are not easily separable from their context 
(Easton, 1995; Eisenhardt, 1989; Halinen&Törnroos, 2005; Yin, 2009). Since the in-
volvement of many stakeholders is needed in the commercialization of a product of a 
functional food industry due to its relatively sensitive health context, case study method 
is a good way to show various points of view of each stakeholder, their impacts, and how 
they influence the whole process. In this thesis, empirical observations from the case 
study and the existing literature are combined to extend the knowledge on commerciali-
zation and stakeholders.  
A single case study of an organization in functional food industry is conducted in this 
thesis. According to Yin (1994), single case can contribute to knowledge and theory-
building. Such a study can even help to refocus future investigations in an entire field. 
The reason for selecting a single case rather than a multiple case study is that the investi-
gator has access to a situation that is previously inaccessible to scientific observation. 
Moreover, a multiple-case study might require extensive resources and time. The single 
case study is thus worth conducting because the descriptive information alone will be 
revelatory (Yin, 1994). In our study, we are conducting interviews with several stake-
holders to find out their activities and motives for performing those activities, which is 
not discovered in previous studies, thus a single case study approach suits best in our 
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research. Our study reveals the interactions between organizations and individuals, focus-
ing on one focal company in the center of other organizations as an orchestrator. 
3.2 Data Gathering 
According to Gummesson (1993), the general reason for doing case study research is to 
better understand complex phenomena. He states that in case study research, qualitative 
methods are often used for data generation, which may have given rise to the notion that 
case studies are mostly qualitative. Case studies may also benefit from quantitative meth-
ods. 
Qualitative data can be gathered using the following methods:  
 Existing materials 
 Questionnaire surveys  
 Qualitative interviews  
 Observation  
 Action Science  
There is not only one option to use these methods. Therefore, in practice a combination 
of the methods are used when gathering the data (Gummesson, 1993). First, in existing 
material data gathering method, books, photos, web pages and statistics can be used. The 
advantage of this method would be saving time, as someone already has made the data 
input. Second, questionnaire surveys lead to better qualitative interviews. By the applica-
tion of these surveys, interviews are being more standardized and formalized. Question-
naires can give answers to the questions such as how much, how many and how often. 
They are mostly useful for clearly defined problems. Third, interviews are the most com-
mon method of qualitative data gathering. The topics that will be covered should be stud-
ied well before the interview is conducted. Although there are similarities with question-
naires such as interaction of people, interviews take place in a more informal way than 
questionnaires. Interviews yield direct quotations from people about their experiences, 
opinions, feelings, and knowledge (Patton, 2005). Fourth, in observation method, the data 
can be gathered using all the five senses of the researcher. This method is used to gather 
data which is not available by expressing in words. The advantage of this would be ac-
cessing information that is not provided in anywhere else. It consists of detailed descrip-
tions of people’s activities, behaviors, actions, interactions, and organizational processes 
(Patton, 2005). Fifth, in action science, in other words in action research, other methods 
of data access must be examined, which are interviews and observation. Active partici-
pation is needed. Usable knowledge that can be later applied and validated in action 
should be produced. In this thesis, the use of existing materials and qualitative interviews 
are employed as the main method of data gathering. 
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Interviews and focus groups are the most common methods of data collection used in 
qualitative research (Gill et. al., 2008). According to Patton (1990), the purpose of inter-
viewing is to allow the researcher to enter into the other person’s perspective, and the 
quality of the information obtained depends on the interviewer. There are three funda-
mental types of research interviews: structured, semi-structured and unstructured. In this 
thesis, semi-structured interviews are used, which consist of several key questions that 
help to define the areas to be explored, but also allows the interviewer or interviewee to 
diverge in order to pursue an idea or response in more detail (Gill et. al., 2008). Semi-
structured interviews allow researchers to go with the flow while asking pre-determined 
questions to obtain the information. According to Flick (2009), in qualitative interviews, 
narratives can be used to elicit a more comprehensive and contextualized account of 
events and experiences, and this can be achieved with either overall life histories or situ-
ation-oriented narratives. He states that there are different ways of conceiving narratives 
in interviews: either as the main form, standing alone, or embedded in different forms of 
questions. Sometimes other forms of accessing experiences might be needed to comple-
ment, or even replace, narratives.  
To increase the legitimacy of the case study, author used various data collection methods. 
As secondary data, existing literature on commercialization and stakeholders, scientific 
research on plant stanols that is published in various journals, innovator firm’s website 
for comprehensive information on the relevant stakeholders, publicly accessible docu-
ments and books for determining the related actors and for understanding the overview 
of functional food industry and its products were used. In addition to the secondary data, 
semi-structured interviews with open-ended questions with internal and external stake-
holders, and observations throughout the thesis were employed. In total, 7 qualitative in-
terviews were conducted with regulatory bodies, doctors, scientists, a research organiza-
tion, innovator firm, and licensing partners as the primary source of data generation in 
this research. Four of the interviews were conducted in interviewee’s offices face-to-face, 
while 3 of the interviews were conducted on Skype due to the limited availability of the 
interviewees and the distance between the interviewer and interviewees. All the conver-
sations were recorded with the interviewee’s consent. Different interview questions were 
designed depending on the actor type. As an overview, the questions are designed in ac-
cordance with the research questions of the thesis, with the aim of learning about the 
informant’s activities and their motives on performing those activities. The questions 
were later improved after reviewing them with the thesis supervisor. Before the inter-
views, the activities of the organization of the interviewees and the projects they are cur-
rently or previously involved were thoroughly examined to know more about the inform-
ants. All the interviews were conducted in 4 month time period and about 5 hours 30 
minutes of interview recordings were transcribed for analysis. The dates and lengths of 
the interviews are listed in Table 8 below. 
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Table 8. Details about interviews. 
Interviewee Role Date Duration 
Leena Mannonen, 
Anne Haikonen 
(MMM) 
Commercial and Legislative Coun-
sellors (Food Division, Food 
Safety Unit) 
26.04.2018 52 mins 
Nesli Sözer (VTT) 
Principal Investigator (Plant 
based proteins) 
27.04.2018 20 mins 
Pekka Puska Former Director General of THL 21.05.2018 45 mins 
Susanna Rosin 
(Raisio) 
Science and Nutrition Communi-
cation Manager 
11.06.2018 52 mins 
George Crocker 
(Olivio USA) 
General Manager 13.06.2018 45 mins 
Donny Bambang 
Iryanto (Kalbe Nu-
tritionals Indone-
sia) 
Business Unit Head 25.07.2018 35 mins 
Helena Gylling 
Contributor to the research of 
plant stanols 
04.07.2018 87 mins 
 
The interviewees were selected based on their experience and their high degrees of con-
tribution to Benecol’s commercialization process over 20 years, except the research or-
ganization. The informant from VTT in this research acted as a general information pro-
vider who is involved in the improvement of plant based foods, which is in the similar 
ingredient category as the Benecol’s main ingredient, plant sterol ester. The selected in-
terviewees were the major stakeholders that influenced large masses in terms of the in-
gredient’s scientific validity and health claims, and helped Benecol for its dissemination 
in Finland and abroad. The informants were sampled and chosen after the inventor of 
Benecol provided the names of relevant actors who were involved in its commercializa-
tion. After receiving the names of the relevant actors, author ran an extensive web search 
to access their contact details. Following this process, the informants were contacted and 
the interview dates were set. In order to reach licensing partners in other countries, Olavi 
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Erkinjuntti’s help was needed, who is the director of rest of the world business in Raisio. 
The list of interviewees is shown in Table 9 below. This data is gathered through the 
websites of the mentioned organizations in the list and the role of the individuals is ob-
tained through their corresponding organization page.  
Table 9. List of interviewees. 
Actor Type Organization Name Role 
Regulator 
Finnish Ministry 
of Agriculture and 
Forestry 
Leena Mannonen 
Commercial Counsellor (Food Di-
vision, Food Safety Unit) 
Regulator 
Finnish Ministry 
of Agriculture and 
Forestry 
Anne Haikonen 
Legislative Counselor (Food Divi-
sion, Food Safety Unit) 
Research  
Organization 
VTT Nesli Sözer 
Principal Investigator (Plant 
based proteins) 
Opinion 
Leader 
National Institute 
for Health and 
Welfare (THL) of 
Finland 
Pekka Puska Former Director General of THL 
Innovator Raisio Susanna Rosin 
Science and Nutrition Communi-
cation Manager 
Licensing 
Partner 
Olivio USA George Crocker General Manager 
Licensing 
Partner 
Kalbe Nutritionals 
Indonesia 
Donny Bambang 
Iryanto 
Business Unit Head 
Scientist Biomedicum Helena Gylling 
Contributor to the research of 
plant stanols 
 
Flick (2009) argues that in an interview, interviewees should be given as much scope as 
possible to reveal their views. At the same time, they should be given a structure for what 
to talk about. Careful consideration should be given to the wording of each question be-
fore the interview (Patton 1990). In a qualitative interview, good questions should be open 
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ended, require more than a yes/no answer, neutral, and understandable. It would make 
sense to start with easy questions to let interviewee build up confidence and then further 
proceed to more sensitive questions. A very important step is planning for probing inter-
viewees. Before the interview, respondents should be informed about the study details 
and confidentiality of the interview (Britten, 1999). Questions should be reformed, if the 
interviewees' answers remain too general or if they miss the intended point. There are 
some key points for evaluating interview questions (Flick, 2009): 
 Why this specific question is asked?  
 What is its theoretical relevance?  
 What is the link to the research question? 
 Is the question easy to understand?  
 Is the question unambiguous?  
 What is the relation between single questions? 
3.3 Data Analysis 
The interview transcriptions acted as a base for analysis for the results part of the thesis 
on the activities and motives of the stakeholders. The results from the interviews were 
analyzed by making comparisons of each stakeholder group and mapping the connection 
and relationship between them that affected the course of events throughout the commer-
cialization process. Apart from the interviews as primary data source, books, journal ar-
ticles and company’s website were used to gather required information and to analyze the 
informants’ statements. As the data of the study is qualitative, the frameworks created in 
this thesis are based on the interpretations of the author, following the gathered infor-
mation from the interviewees and from the secondary data that explains the functional 
food ecosystem and the key players that influence the interactions. 
3.4 Case Company 
The case company of the thesis is Finnish food manufacturer Raisio that manufactures 
the cholesterol lowering margarine Benecol, which is sold in 30 countries worldwide. It 
has 120 different product variations, which are spreads, yogurts, mini drinks, cereal 
(grain) products, cheese, coffee, instant drink powder, milk drink, and food supplements. 
Products are tailored for the local market needs of the countries they are sold in, and 
manufactured by the well-established local companies, containing the essential ingredient 
plant stanol ester in each product. Benecol proved its success in international markets 
short after the discovery of its main ingredient, plant stanol ester, in 1989 in Finland. Plant 
stanol ester was created by Dr. Ingmar Wester from Raisio, and the first Benecol product 
that contains the ingredient was launched in 1995.  
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We selected this extreme case, a radical innovation, which is a functional food and a novel 
product category between food and medicine that needs support from diverse stakehold-
ers at global market settings for its effective commercialization. This case presents a good 
base for investigating the activities of diverse stakeholders due to several reasons. First, 
as Benecol is a vegetable fat spread that lowers cholesterol with its unique ingredient 
plant stanol ester and categorized as a functional food, its market launch had difficulties 
in some countries regarding regulations as the health is concerned. Therefore, multitude 
of stakeholders were involved in its commercialization process over the years. Second, 
plant stanol/sterols were among 10 greatest innovations in nutrition research between 
1976 and 2006, and lots of medical studies and experiments were conducted by primary 
healthcare actors to test the viability and the positive health effects of the ingredient. 
Lastly, Benecol was one of the first functional food product that is considered as a dis-
ruptive innovation, which created a new market category, and attracted many people from 
around the world. It attracted various licensing partners in different countries, hence in-
teractions between these actors in international settings provide a good base for the in-
vestigation of their activities. 
Plant stanol ester's cholesterol-lowering effect has been proven in over 70 clinical studies. 
It lowers blood LDL cholesterol by blocking the absorption of cholesterol in the small 
intestine. The first study that showed the 12 month sustained effect was published in 
The New England Journal of Medicine (Miettinen et. al., 1995). According to this study, 
a daily intake of 1.5-3 grams of plant stanols reduces serum total and LDL cholesterol 
levels dose-dependently by an average of 10%. Apparent effects can be seen after 2-3 
weeks of daily consumption and it is sustainable as it is consumed daily. The reduction 
of 10% in LDL cholesterol levels is made possible by the daily intake of 2 grams of plant 
stanols, as it reduces cholesterol absorption by approximately 40–50% (Gylling et. al., 
1997). The effects of the 12 month consumption of plant stanols can be seen in Figure 7 
below (Miettinen et. al., 1995). 
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Figure 7.  Serum cholesterol levels before and after the consumption of margarine with and without sitostanol ester for 12 months (Miettinen et. al., 1995). 
In the figure above, the line with the circles represents the control group that consumed 
the margarine without the plant stanols. The line with rectangles represents the group that 
consumed 2.6 g of sitostanol per day and the other line with triangles represents the group 
that consumed 1.8 g of sitostanol per day. The study proved that continuous consumption 
of plant stanols has an effect on cholesterol reduction. 
After Raisio’s substantial success in Finland, the company started licensing out the ingre-dient for international expansion in United States (US), and faced various challenges re-
garding the regulation, policies, and creating awareness among consumers in 1999. 
Raisio’s licensing partner in US, McNeil Consumer Nutritionals, had decided to market 
Benecol in the US as a dietary supplement to take advantage of the dietary supplement 
regulations which allows stronger health claims on packaging for these type of products. 
However, Food and Drug Administration (FDA) of US did not agree with McNeil that 
Benecol was a dietery supplement, and stated that it is subject to US food regulation. This 
strategy in US caused a delay of 6 months in Benecol’s launch and even after the launch, 
it could not attract customers and sales were under the anticipated levels. The price of 
Benecol was much higher than its competitor Flora. Although the health claims were dif-
ferent for these 2 products, Flora had a more appealing packaging with a heart-shaped 
logo and more attractive sales price than Benecol. On consumers mind, the effect of Ben-
ecol was not well understood to justify the price premium of 4-5 times of the regular 
products (Mellentin & Heasman, 2001). After the disappointing experience in interna-
tionalization in US, in the beginning of 2000, Raisio announced that it would take over 
responsibility for Benecol’s marketing in the Baltic region (Sweden, Norway, Denmark, 
Poland, Russia and Iceland) along with the Finnish market.  
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After EFSA’s (European Food Safety Authority) approval on the health claims in 2004 
for plant stanol ester that it reduces cholesterol and thus reduces the risk of coronary heart 
disease, Benecol has been expanding in Asia and Europe with new licensing partners. 
The timeline of important events throughout Benecol history is illustrated in Figure 8 
below.  
 
Figure 8. Milestones in Benecol timeline. 
In early 2018, Raisio management restructured the whole company and reorganised op-
erations. The main change was the integration of all Raisio’s food brands and businesses 
into the Healthy Food Division. This means the discontinuation of the Healthy Food Units 
which included Benecol Unit. There used to be a separate division for Benecol and there 
have been different types of structuring throughout the years but now there is only one 
division with all the products. This include not only Benecol products but also other grain 
based products and everything is under the same division. 
3.5 Research Process 
The thesis work was completed in 7 months. The research process was divided into three 
main phases, which includes literature reviews and secondary data gathering, interview 
preparation, primary data gathering and data analysis, and finalizing thesis. The timeline 
is illustrated in Figure 9 below. 
 
Figure 9. Timeline of the research process. 
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The thesis work was officially kicked off on 15 February 2018. In the first two months, 
the focus was on theoretical research and gathering the secondary data. In this stage, 
more information about the case company and about its innovation were gathered to get 
familiar with its processes. After two months of theoretical research and literature re-
views, interview questions were prepared and interviewees were contacted. The inter-
viewing process took four months and seven interviews were conducted during this pe-
riod. Qualitative data that was gathered from interviews acted as a foundation for the re-
sults part. Final editing was made in the last stage of the research and the thesis was fi-
nalized on 19 September 2018. 
3.6 Evaluation of the Research 
The scientific generalization from a single case might not be relevant as the scientific 
facts are rarely based on single experiments; they are usually based on a multiple set of 
experiments, which have replicated the same phenomenon under different conditions 
(Yin, 1994). There might be some bias in the interviewees’ comments since they might 
have wanted to keep some of the sensitive information to themselves in order to protect 
their companies from possible interrogations. Furthermore, especially when explaining 
their motives, interviewees might have not shared the true reasons behind their activities 
for the focal company, due to the fear of being wrongly judged by people. Also, in order 
to not to jeopardize their relationship with the innovator firm, the informants might have 
not revealed their true opinions and they might have only expressed their positive inter-
pretations. We acknowledge that such limitations might exist in the research and it is 
difficult to sense if the opinions of the key participants of this study reflect their own true 
views. 
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4. RESULTS 
 
The results of the study is structured according to the research questions that are presented 
in sub-chapter 1.2. In this results section, the sub-chapters represent the relevant stake-
holders that has a role in the commercialization process of Benecol throughout the years. 
In each sub-chapter, their activities, their motivation behind those activities, the projects 
they were involved, and the scope of the organization they represent are explained in 
detail. The stakeholders that have a direct influence on Benecol are: Ministry of Agricul-
ture and Forestry of Finland by regulating the marketing of a food product in Finland and 
the associated legislative work as well as providing guidance to the companies on the 
authorization procedure; Evira by evaluating the novelty of the product and associated 
risks on country level; EFSA by evaluating safety assessments and the validity of the 
health claims as well as giving advice on risk management decisions that are made by 
European Commission; opinion leaders by trusting the product, promoting and dissemi-
nating its use for well-being of people and influencing the major healthcare actors; mar-
keting and nutrition communication managers by communicating the health benefits of 
the product to several healthcare professionals around the world for adoption; licensing 
partners by distributing products in overseas and making them available for users; and 
scientists by validating the health claims and revealing positive health effects of the prod-
ucts. 
4.1 Regulatory Environment 
An interview was conducted with legislative and commercial counsellors in Ministry of 
Agriculture and Forestry (MMM) in Finland and according to the information provided, 
the regulatory environment in novel food industry consists of Evira, MMM, EU Member 
States, and EU Commission. In this context, the areas of expertise and the scope of work 
of the related organizations is listed in Table 10 below. 
Table 10. Focus areas of organizations. 
Organization Scope 
MMM (Ministry of 
Agriculture and 
Forestry of Finland) 
MMM is responsible for the legislative work on food products as part 
of the Finnish Government and it is working with EU institutions for de-
cision-making. 
Evira (Finnish Food 
Safety Authority) 
It is a centralized body operating under the Ministry of Agriculture and 
Forestry in Finland. It conducts risk assessments and scientific research. 
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EFSA (European 
Food Safety Au-
thority) 
The European Food Safety Authority is the agency of the European Un-
ion that provides independent scientific advice and communicates on 
existing and emerging risks associated with the food chain. 
European Commis-
sion 
The European Commission is an institution of the European Union, re-
sponsible for proposing legislation, implementing decisions, upholding 
the EU treaties and managing the day-to-day business of the EU. 
 
Among these organizations, Evira and MMM represent the main bodies in Finland in 
terms of novel food regulation, and EFSA and European commission are higher level 
regulatory authorities. In this regulatory chain, although the last decision is made by Eu-
ropean Commission, EFSA has the highest authority and has the most influence on a 
marketed product regarding safety assessments and the validity of the health claims. The 
authorization procedure of a novel food in Finland is illustrated in Figure 10 below. 
 
 
Figure 10.  Authorization procedure for novel foods in Finland. 
The authorization process of a novel food in Finland starts with the innovator firm’s ap-
plication to Evira for the assessment of the novelty of the product. Anne Haikonen, leg-
islative counsellor from MMM explains the process as follows: 
“For health claims, there is harmonized authorization system based on EU (Euro-
pean Union) legislation. Evira is the contact point if a company innovates a new 
product and they want to tell about health benefits. They contact Evira to confirm 
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if the claim they want to make is considered as a health claim and then they make 
an application. Evira sends it to EFSA (European Food and Safety Authority). 
Then EFSA is responsible for the scientific assessment and the decision will be 
made on the EU level commission regulation. Only health claims authorized within 
this system can be used.” 
In Benecol’s case, as they came to the market prior to the novel food regulation in EU 
that took place in 1997 for safety assessments, Benecol had the chance to skip the author-
ization procedure for their products. Proper use of the food was company’s and consum-
ers’ responsibility. Leena Mannonen, commercial counsellor from MMM, explains the 
situation: 
“For Benecol case, the process was a bit different. Benecol entered the market 
before 1997 and it is enough to call it old food with regards to novelty. So there 
was no authorization for Benecol products apart from the claims. There were some 
labelling criteria set for all similar phyto sterol/stanol products, and Benecol ap-
plied to those as well. But for the authorization process, there was none for Bene-
col for proving safety. For health claims, the authorization were needed. The com-
pany was responsible for the safety issues before 1997. Although we evaluated 
beforehand, proper use of the food was company’s responsibility. For novelties, 
we decided to have this regulation for pre-authorization assessment. The health 
claims regulation took into effect in 2007. First safety came (1997), and then reg-
ulating.” 
Leena Mannonen also points out that with the new regulation for novel foods in European 
Union that came into effect in 1 January 2018, a centralized system started to be used for 
the health claims. She talks about the new regulation: 
“We have a new regulation (EU) 2015/2283 on novel foods and it is applicable 
started from this January. It is a centralized system in Europe. Before, it was de-
centralized and only for one company who requested authorization. But now ap-
provals are generic so anybody, if you find your product (ingredient) in the list 
within the specifications, you can bring your product into the market. When the 
claim has been authorized, anyone whose product fulfills the criteria can use those 
claims. Before January 2018, it was up to the member states to evaluate the safety 
and to authorize the products. Now, these systems can be parallel and they are 
hoped to a certain extent to be parallel if there is a possibility that company wants 
to claim exclusivity for the food and the claim for 5 years. Then especially we try 
or EFSA and the commission try to make systems go parallel. So the 5 year period 
would be same for both but we have never tried that yet so we don’t know if it 
works. Validity lasts for 5 years for the health claim if it fits into the criteria.” 
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The new regulation introduces convenience to many larger-scale companies who can fit 
their products into the criteria. They are more willing to go through the authorization 
processes, compared to the smaller scale firms. According to Mannonen, larger scale 
firms tend to claim the safety of their innovations to attract more customers. However, it 
might be challenging for small enterprises, as the research and development takes up re-
sources. Some companies might not be eager to go through the assessment process. Some 
try to avoid, and some try to go through this authorization. Leena Mannonen talks about 
the future of the new regulation and how they are working on specifications to make it 
easier for new entrants:   
“It is early to say how things will proceed. Now we have just prepared the initial 
list of authorized novel foods. Tricky part is to draft the specifications. Only if the 
product fits into the specifications, you can benefit from the authorization. Speci-
fications is not perfect yet because they are based on the old authorizations. And 
they were prepared for one particular company, which makes it not helpful for 
anybody else. But in the long run, we will try to draft the specifications in a way 
that it would be easily fit for other companies’ products as well. Proof of safety is 
crucial because we need to have some sort of control what we have assessed as 
safe and what we can authorize. It will be forming somehow in the coming few 
years. It is helpful for all companies but also it might be hard to fit your product 
within specifications.” 
The interest in functional foods has been decreasing since early 2000 due to the strict 
regulations of the authorities. Leena Mannonen points out: 
“Ever since we got the regulation, which was fairly strict for functionality, EFSA 
is quite strict in assessing the functionality and proof of functionality. I think that 
is why interest is decreasing because criteria were too high. We didn’t or anybody 
didn’t anticipate the high standards EFSA has set. Before 1997, the regulations 
were on national level for anything that was authorized. In Finland, we had a vol-
untary system for a couple of years. A group of professors were used for evaluation 
of functionality and it was on voluntary basis. Proving the functionality was too 
difficult because EFSA’s criteria was too high. If you prove and go through 
EFSA’s authorization, you have European wide markets.” 
These strict policies applied by regulators limited the potential for goals-driven participa-
tion by innovator firms and decreased their willingness to invest in research and develop-
ment due to the regulatory uncertainty of whether the regulators would approve the prod-
ucts or not. Because the statistical methods that were used by innovator firms were the 
first ones of its kind, the regulators were not familiar with them and they invalidated the 
research which caused the companies to stop using a health claim. Regulators require a 
link between a product and a positive health effect of that product, which means it is 
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causal-based model, and regulators consider that as a reference for category assessment 
and boundary drawing (Granqvist & Ritvala, 2016). 
It seems that the new regulatory environment of novel foods, which is changed in the 
beginning of 2018 with the introduction of the new legislation (EU) 2015/2283 in EU, 
will make the authorization and commercialization process of a novel food easier. The 
new centralized system allows companies to market their products with a specific ingre-
dient in any EU country, once a company obtain the rights to use the health claims for 
that particular ingredient after the safety assessments conducted by EFSA. Then the in-
gredient goes into the database and the list of authorized novel foods as safe for any com-
pany to use the same ingredient in their products. The convenience the new legislation 
provides the companies is that once they find the ingredient they use in the product in the 
novel food list, and once it passes the safety assessments, they can directly start marketing 
the product in any country in EU they wish to sell it. This new system might increase the 
competition between the companies, but it is anticipated that the distribution of the prod-
ucts for sales among different EU members will be easier. Moreover, since the policies 
seem to be less strict than it used to be, it might contribute to the innovation and re-
search/development activities of food companies and encourage them to take initiatives 
to be more active in the industry. 
4.2 Scientists 
In order to get a scientist perspective on the commercialization of Benecol products 
throughout the years, an interview was conducted with Helena Gylling, who is notably 
one of the most influential persons that contributed to the scientific research and validity 
of the health claims of plant stanols, which is the main ingredient of Benecol product. 
Gylling’s work on plant stanols and experiments she conducted with different doses of 
daily consumption uncovered the health benefits of plant stanols, which placed Benecol 
on top of its market and attracted many audiences from all over the world. She was also 
involved in many cardiovascular seminars and conferences around the world and ex-
plained positive health effects of plant stanols to many healthcare professionals, which 
promoted the dissemination of the innovation in plenty of markets, as she is a recognized 
scientist and has a high reputation in the field of plant stanols. She explains how she was 
involved in plant stanol studies as well as her contribution to Benecol:  
“Professor Miettinen was the chief of the department of internal medicine at the 
university hospital. When I went to do my residency in internal medicine, I also 
joined his research team. Then, I specialized in internal medicine and became a 
senior lecturer and worked in the hospital. Then I went to United States for a cou-
ple of years to do research there with cholesterol metabolism. Tatu Miettinen has 
started the Benecol research and when I came back, I automatically jumped in to 
these studies.” 
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For stanol to take its form to be added in the margarine, they need to be converted from 
sterols with a chemical reaction, which is the basic form of stanols. She further explains 
how their research all started with plant sterols and the discovery of the ingredient:  
“I came from United States in 1990 and I joined Tatu Miettinen's research group 
and participated to Benecol studies starting from 1990. Tatu Miettinen was mainly 
working on cholesterol metabolism. He was doing very extensive studies on how 
cholesterol is absorbed, how it is synthesized, how it is circulating in the body, 
also in several diseases like atherosclerosis in which the arteries are calcified and 
cholesterol is the main reason of this calcification which causes heart attacks. In 
1980's, a forest industry company, Kaukas’ manager contacted Tatu Miettinen and 
offered him to make use of the wood waste that is left after processing. Sitosterols 
are generated in the trees and that is how the research group received sitosterol 
to analyze the substance and to convert it to sitostanol. When it succeeded, he 
contacted Ingmar Wester and Ingmar continued to esterify sitostanol.” 
Converting sitosterols into sitostanols is a costly process and even sterols could be used 
in the products without its conversion into stanols. However, the problem with sterols 
was that in the studies that were conducted between 1950 and 1970, when sitosterols are 
ingested, and when they are eaten in large amounts, due to its crystal line form the levels 
in the body increased a lot. Additionally, in animal studies the scientists were thinking 
that it caused also harm to coronary arteries and blocked them, which is a disease called 
atherosclerosis. The studies on the effects of sitosterols on human body took place be-
tween 1950 and 1970, and they were very well examined in that 20 year time. However, 
according to Gylling, at the moment scientists are a bit skeptical about whether these 
studies on sterols were accurate or not, since Unilever is using sterols in their products 
and proving that it has no negative effects on human body. Gylling’s recent studies also 
support the sterols’ safety. Even though Benecol was the first product of its kind that 
reduces cholesterol and it came to market before Unilever’s Becel Proactiv, which also 
reduces cholesterol with its sterol ingredient and has the same positive health effects, 
Gylling explains the motivation and the reason behind the idea of sterols conversion into 
stanols to incorporate it in the first Benecol products: 
“Even though the consumption of sitostanols or sitosterols of 2 grams per day have 
the same cholesterol lowering effect by 10%, sterols are absorbed in intestine 
about 10%, while stanols are absorbed about 0,01%. Despite the fact that stanol 
absorption is 1000 times lower than the sterols, since the exact amount of the ab-
sorption in both situations is considerably low, they are both claimed to be safe to 
use. Tatu Miettinen had the chance to choose between sterols and stanols to incor-
porate in the margarine and he chose stanols due to its very slight effect. It doesn’t 
harm the arteries at all, not even a tiniest bit. However, no one can say that eating 
2 or 3 grams of sterols per day is harmful.” 
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There are several advantages of using stanols over sterols: First, it reduces cholesterol, it 
is very little absorbed, its levels in our body are very low and it lowers plant sterols. In 
addition to these benefits, with 9 grams sitostanol consumption, we get 17% of cholesterol 
reduction instead of 10%, which is not the case in plant sterols. Although stanol offers 
higher reductions in cholesterol with higher amounts of consumptions, the use of it is not 
recommended by regulators due to the low number of studies conducted with higher 
doses. However, most of the doctors say that it would be good if the recommended 
amount was increased to 5-6 grams from 2-3 grams, because there are no side effects. 
The scientific contribution of Gylling’s studies to Benecol is explained by her own words: 
“I was mainly in touch with the patients. I was doing the clinical work with the 
patients and what I did was separating the low density lipoprotein (LDL) particles 
and high density lipoprotein (HDL) particles from blood and I labelled them with 
iodine by that time. Then I injected them back to the patients and then we followed 
how they disappeared from their blood so we could construct how the sitostanol 
affected the metabolism of LDL and HDL particles. With European Atherosclero-
sis Society, we tried to investigate in the long-term, whether plant stanols or sterols 
are accumulating in the arterial wall and cause heart attacks or reduce the amount 
of new heart attacks. The studies showed that there are no negative effects of plant 
sterols and stanols. We have been using surrogate markers and measuring the 
functionality of the arteries with different type of equipment. Then we have been 
analyzing the plaques, which blocks the arteries. We were also analyzing the vas-
cular effects of Benecol, and measuring how the arteries are functioning before 
and after the use. We saw that in some groups, in men, there was a slight improve-
ment in small arteries. We measured how much blood enters to the very small area 
in a limited time.” 
Gylling was also involved in many publications about plant stanol in which Bene-
col was mentioned. She describes her contribution to Benecol in the last 20 years 
by her publications, her speeches in various conferences, and also by promoting 
its health effects in several journals: 
“I joined the team 2 years after they started the research. My first Benecol study 
came out in 1994, one year before Benecol was launched, and since then, I have 
been involved in 60 articles. The landmark study came out on the same day Bene-
col was launched in Helsinki. I was in United States, in American Heart Associa-
tion meeting and giving a talk about Benecol. Everybody was so interested. We 
have been writing about Benecol several times in our Finnish journals for medical 
personnel. Tatu and I wrote several papers in the Finnish journals when the Ben-
ecol was new and when the stock price of Benecol was the highest. There was huge 
amount of articles in our papers about this big business. I have been talking about 
Benecol in several congresses all over the world in the last 20 years.” 
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4.3 Research Organizations 
Research organizations can support product development activities of innovator compa-
nies and take part as an additional resource with their knowledge and expertise. In order 
to examine the research environment in novel food industry in Finland and the activities 
a research organization perform, an interview was conducted with a principal scientist 
working in the field of plant based proteins in VTT Technical Research Centre. VTT 
Technical Research Centre of Finland is a leading research and technology organization 
in Europe and in Finland. Plant based proteins is one of the research areas in the organi-
zation in which they develop food products and ingredients with protein claims. Accord-
ing to the interview conducted, research organizations are highly involved in commercial 
projects with companies and they have influence on the processes. Nesli Sözer, a principal 
scientist at VTT, explains the different type of projects they deal with:  
“With companies we have different type of projects. The projects where the com-
pany is sole financer, and those projects are mostly kept confidential. They are 
down with the particular needs of the company as a research & development pro-
ject. But we have also those projects which is jointly funded like co-creation pro-
jects which is kind of similar to what Business Finland is having at the moment. 
But our projects are without Business Finland. In those projects we develop a pro-
ject idea based on mutual interest. And as a research company, we are not doing 
any production or any product launches in market. Sometimes we might have 
spinoffs but that is very rare in the food field.” 
She points out that, in VTT, they are taking part in the development processes in different 
ways, depending on the type of the company who applies to VTT for a food modification. 
She states that the companies that apply to VTT are either ingredient companies or food 
manufacturing companies. If it is a food ingredient company, the ingredient that the com-
pany wants to use in their products can be analyzed, developed, modified and adjusted 
for the needs of the company to meet the requirements of the health claim regulations or 
to meet the nutritional levels the company wants to achieve. She explains the processes:  
“We may be involved in either ingredient or product development. We might also 
help with the processes they have. Pretty much depends on the portfolio or the 
background of the company. So if it is an ingredient company, we take part in 
ingredient processing, ingredient modification and functionalization, and improv-
ing its applicability. But if it is a food manufacturing company, then we take part 
in the food matrix design. For instance, what we can do for a company is that when 
they come to us and ask to have high fiber claim in the bread (product), we do 
functionalization, recipe and process development for that company, so that they 
can have fiber claim in their bread. We know the required amount of the ingredient 
that needs to be present in the product per serving or per grams. Since VTT is quite 
multi-disciplinary research organization, we are also helping on team level which 
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is focusing on servitization so it also concerns how to communicate with the con-
sumer. We also have different teams that focuses on the packaging. We have sci-
entists who are experts on nutrition. And we also do interventions together with 
our collaborators from universities.” 
For the safety related analyses, it is possible for VTT to take part in measuring the toxicity 
levels in ingredients. However, Evira is the head organization if some trials are needed as 
they are responsible for safety assessments for food products in Finland. She gives an 
example from an emerging initiative, which is using wood ingredients for food applica-
tions: 
“We have initiatives like wood to food for utilizing wood components for food ap-
plications, meaning substances like lignin and nano-cellulose. Although cellulose 
has food applications, nano cellulose and lignin are not approved as a food mate-
rial at the moment. Since we are not taking part in the commercialization path, we 
can only instruct companies who are interested in wood ingredients for food ap-
plications, as an example. They need to file the dossiers that will clear out the 
novel food legislation and so on. The tests and analysis of the safety of the ingre-
dients are evaluated by Evira and also by other organizations.  We can only pro-
vide some help and assistance.”  
Lastly, she explains the motives for performing her research and how the activities per-
formed for other companies contribute to the goals and interests of VTT: 
“We are an organization running business based on research so that is our main-
stream business. We also have government support and prioritize helping Finnish 
companies. In the end of the day, we are aiming to contribute to the Finnish econ-
omy and that’s our role within the society. Developing new technologies for well-
being of people and creating new business ecosystems.”  
4.4 Experts as Opinion Leaders 
The interview was conducted with Prof. Pekka Puska, who is the former Director General 
of the National Institute for Health and Welfare (THL) of Finland in 2009-2013, and for-
mer head of National Public Health Institute of Finland (KTL) in 2003-2009. Pekka Puska 
was also the director of North Karelia Project that was initiated in 1972, which was an 
initiative that succeeded to lower the male cardiovascular mortality by 68% in 25 years 
in North Karelia region and then in all Finland. In the project, in order to reduce the high 
mortality rates caused by cardiovascular disease, several different strategies were used. 
Innovative media and communication activities were performed. Systematic involvement 
of general practitioners and public health nurses was practiced. Collaboration with food 
industry, regulators, and national health authorities also played a vital role (Puska, 2002). 
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Puska also conducted studies on different risk factors of cardiovascular disease, such as 
saturated fat consumption, smoking, and alcohol consumption.  
Due to his studies in cardiovascular diseases and his success in improving the healthy diet 
of a nation, Pekka Puska was later involved in commercialization activities of Benecol. 
He took part in some conference speeches and annual meetings of Benecol’s licensing 
partners, explaining the positive health effects of the Benecol’s main ingredient, plant 
stanol ester, which helps reducing the cholesterol levels. He points out how the change in 
people’s eating habits starts with the change in products, and how the growing trend and 
mindset of healthy eating among people attracted some companies in the industry: 
“We spread a lot of all kind of health information but we realized that this was not 
enough. We need products to comply so that it will be easier for people. Not just 
to change them but change the products. So we started population surveys within 
this big project (North Karelia). In the beginning, when we contacted the dairy 
and meat factories to reduce the fat levels, nobody was interested. But gradually 
when our message became more and more popular, some companies started to 
think maybe there's some business possibilities. And so companies started first in 
North Karelia, then national level. They started to think about products that com-
ply with the message and contacted us.” 
The importance of contacting all the relevant stakeholders and involving them to create 
awareness is once again emphasized here in North Karelia Project. In order to change the 
diet and eating habits of a population, various organizations should step up and cooperate 
for the same goal. However, the interests of these organizations must be in line with the 
goals of North Karelia Project. The aim of the project was to reduce the mortality rates 
caused by cardiovascular diseases, and the most significant organizations that would play 
a role in this goal were the food manufacturers and policy makers, as well as the consum-
ers. In North Karelia case, the awareness was created by the media and Ministry of Health 
of Finland. Later on, the apparent demand from the consumer side triggered food manu-
facturers to act accordingly and this led to the reduced fat levels in food products. The 
illustration of the case can be seen in Figure 11 below. 
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Figure 11.  Demand creation. 
In the beginning, without any clear demand from consumers, food manufacturers were 
not eager to take actions to lower their fat content in their products. However, after con-
sumers showed interest in North Karelia Project, manufacturers had to align their interests 
with the consumers and with the Ministry of Health. Pekka Puska explains more about 
the interaction between public and food producers and how he built a bridge between 
them to communicate their interests: 
“In the beginning of the project, we tried to convince people to change their diet. 
But very soon we realized that industry has much more influence and also policy 
makers, particularly in smoking. Then I started to contact food producers and also 
politicians. They were not interested at first. Then we influenced people. They 
started to influence companies and politicians more. Much of our influence to this 
was through people. And in our media strategy we used that a lot.” 
According to Pekka Puska, the major threat in people’s health and diet is the overcon-
sumption of butter, high fat content of meat and dairy products, and high levels of salt 
consumption. He states that foods that are mainstream and consumed on a daily basis are 
affecting people’s health to a large extent. This kind of foods have more impact on well-
being than functional foods. He explains how functional foods act as a role model for 
meat and dairy producers to lower their fat contents and provide healthier products: 
“My interest and background is in public health. And one big thing about func-
tional foods is that as far as I see, they don’t change public health so much. The 
content of normal foods is more important and has much higher impact on public 
health. For example, people eat so much sausage. This HKScan sausage is fortified 
with rapeseed oil. Even small change in fat or salt is very much of importance. I 
think functional foods act as a spearhead and showing the way to other normal 
food producers. They get a lot of attention. Of course functional foods help a cer-
tain group of people like the ones who have high cholesterol so Benecol is good. 
But it is more important that they really showcase for public health.” 
As the healthy food innovations gained popularity in public and the consumption levels 
increased, other companies in the same field noticed that and tried to innovate new food 
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products or tried to change the content of their food products to fit the emerging trend of 
healthy eating. Pekka Puska played a role in communicating with various food producers 
to take actions on their food contents. He was aware that gradual reduction in salt or fat 
content of the products wouldn’t cause a substantial difference in taste and wouldn’t af-
fect the sales of the companies. After food producers are convinced that consumers would 
still buy low fat products, the shift was either done by reducing the fat and salt levels in 
the products or by innovating novel solutions: 
“A dietary change is partly because people and products change. In Finland, in 
addition to these product innovations, we have dramatic change in normal food 
items. If you take sausage or meat products, the saturated fat level has gradually 
reduced. And salt is even better example. The salt content of Finnish food products 
have gradually reduced. There are specific innovations that we have been involved 
but there's no doubt that Benecol is kind of spearhead and real model. And after 
the commercial success of Benecol so many other companies followed the same 
trend. When fat is concerned, HKScan and Atria both have been doing innovations. 
I have been working particularly with the HKScan. They have been very active in 
their product development. They tell the number of the amount of the saturated fat 
per year in the products that have been reduced, and it is amazing. . But then came 
the idea that in addition to fat, can we change the quality of the fat. I have been 
involved with them too. The idea was to feed their pigs with special food that has 
a lot of rapeseed oil. So the fat of the pig changed to less saturated fat and more 
unsaturated fat, so the quality of the fat got better.” 
As a conclusion, Pekka Puska’s influence on food producers encouraged them to shift to 
healthier products and this didn’t reduce their sales levels. He was one of the most im-
portant opinion leaders for Benecol who influenced the public perception on functional 
foods. With his previous efforts in North Karelia Project on lowering cholesterol levels 
of a population, being a well-known expert in cardiovascular field made people and com-
panies trust him and also trust his recommendations.  
4.5 Marketing Managers 
To better understand the case company’s point of view and their activities, an interview 
was conducted with Susanna Rosin, science and nutrition communication manager of 
healthy food division in Raisio Group. She talked about the target customer segments, 
higher sales prices of Benecol due to the special ingredient it contains and how people 
tend to consume healthy foods once they go to routine check-ups and become aware of 
their high cholesterol levels: 
“The key target group is people who need to lower their cholesterol through the 
dietary means. Especially the middle aged and a bit older people. It takes some 
years to become aware that you may have some risk factors. Also people get their 
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risk factors measured usually at some point in their early middle ages and then 
they become aware of their possibly elevated cholesterol levels. In the western 
population, approximately 50 percent of the adult population has elevated choles-
terol levels. So it is a big target. We find it important that our products are healthy 
and ecologically as sound as possible. We pay much attention to the overall nutri-
tional profile of Benecol products so that they are not just products that contain 
cholesterol lowering ingredient but the whole nutritional profile of the product is 
good so the product can fit into the nutritional guidelines as well. As for the pricing 
of the products, our products are always a bit more expensive than regular prod-
ucts due to the specific value of cholesterol lowering effect.” 
In Benecol’s marketing communication, both consumer and healthcare professionals’ 
communications are used. According to Rosin, communication towards healthcare pro-
fessionals is of high importance since these experts are influential and can disseminate 
the health benefit information of Benecol products to those who have high cholesterol 
levels and who are in need of using cholesterol lowering products and treatments: 
“Since we have these clear health benefits and a lot of science behind it, we need 
to educate health care professionals who are those people that meet the people 
who find out about their elevated cholesterol. Because high cholesterol is some-
thing you can't feel but you only become aware of it when you have a blood test 
taken and then you get the results. And that happens within the healthcare system. 
So we do also target our messages to the healthcare professionals partly to those 
who meet patients such as primary care practicing health care professionals but 
we also work with opinion leaders who are aware of the latest science within cho-
lesterol lowering and influence the opinions of other health care professionals. We 
have many different kinds of activities towards health care professionals. They can 
include seminars or any kind of marketing activity. They are then developed and 
targeted towards that audience so that we inform them and they trust us and un-
derstand the benefits of using our products. For example, we are also together 
with two other companies, joint cooperative member of the European Atheroscle-
rosis Society which is an organization that organizes congresses and educational 
sessions. We work together with them and also sponsor educational sessions at 
their congresses so we do have different kinds of activities.” 
As for the marketing communications in overseas, there are different approaches based 
on the country healthcare system. The strategy is set based on the features of the 
healthcare system of that particular country and activities are directed according to these 
specifications: 
“There are different kinds of healthcare systems in different countries where Ben-
ecol products are available. So we then find out what the system is and what our 
key target groups in that specific country and then we try to target our messages 
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towards those who meet those patients who then are our target group. We just 
inform them about this way of lowering cholesterol which is also recommended in 
cardiovascular guidelines. So we think it's our job to keep relevant health care 
professionals aware of our products so that they can then utilize this tool when 
they advise their patients in lowering cholesterol.” 
Overall view of activities pointed at healthcare professionals presented that it is highly 
important to train primary healthcare actors for sharing the health benefit of a product 
with the public. As these actors are the ones who are in close touch with the patients, they 
can influence the product diffusion. The challenge here might be to convince these pro-
fessionals to believe in the claimed health effects. Then it is up to healthcare professionals 
to recommend the product to their patients.  
There are many things that influence consumers’ purchase decision such as the taste of 
the product, how they are packaged, how they are marketed, how consumers feel about 
the image of the company and things as such. In general, both healthcare professionals’ 
communication and direct consumer communication have an impact on the efficiency of 
marketing, so they complement each other. How much emphasis is put on each type of 
communication depends on the situation of the country. All in all, having an approved 
health claim within the European Union for plant stanol esters and also in some other 
countries where they have their own health claim legislation is very important both in 
consumer communication and in healthcare professionals’ communication, as getting an 
approval on a health claim for a product is rather difficult and brings a positive brand 
image to the firms who can obtain this valuable key criteria. 
4.6 Licensing Partners 
Interviews are conducted with a selected set of Benecol’s licensing partners to understand 
and capture their perspective on making business and growing with an innovative prod-
uct. The questions are focused to get insights on the motives, goals and interests in the 
partnership with Raisio to incorporate Benecol products in the product range and how 
they are aligned with Benecol's strategy. Furthermore, the following themes are dis-
cussed:  
 Activities and research performed prior to the start of the partnership and the de-cision process 
 Country-specific policies on novel foods and dealing with the regulatory issues 
 Marketing and pricing strategy, and positioning Benecol products in market 
 Views about the functional food industry, its current state in local market and its 
potential for future business opportunities 
 Consumer awareness on plant sterol and the associated health effects 
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Next, the interviews with two licensing partners and their views and opinions about 
the aforementioned topics will be presented. 
4.6.1 Olivio USA 
The first interview with a licensing partner was conducted with Olivio USA. Olivio is a 
food manufacturing company and it manufactures spreads and cooking products under 
the Olivio brand name, and is best known for an olive oil-based margarine-like spread. 
The interview was conducted with the general manager of the company, George Crocker. 
Olivio’s partnership with Raisio started on 1st December 2016 and since then it is the 
main distributor of Benecol products in USA. 
As the consumers’ food preferences are different in USA, and American consumers tend 
to eat less fat spreads, Olivio made some product adjustments on the content of its Bene-
col spread. George Crocker explains the changes in the products to fit the consumer needs:  
“If Becel Proactiv has 1 gr of plant sterols, our Benecol products had 0.5 gr of 
plant stanols in the beginning. Therefore, we increased the amount of the plant 
stanols in our products to make it more effective in lower amounts of daily con-
sumption. Consumers in United States do not consume fat spreads as much as the 
consumers in Finland. If the consumption of the spread is around 2 tablespoon per 
day in Finland, it is one third of a tablespoon in United States. They don’t eat 
margarines in US so we came up with new products such as chocolate chews and 
coffee cream (Nondairy). We need to focus on the products that is consumed more 
on a daily basis.” 
As it can be seen from the Olivio’s product development strategy, the efforts are more 
directed to the products that are consumed widespread. Instead of focusing only on the 
margarines product range which is claimed to be not profitable in USA due to the insuf-
ficient consumer awareness, they tried to penetrate the market with new products that 
they internally developed with Raisio’s patented special ingredient, plant stanol ester, and 
used these products only in that specific country. As coffee creams and chocolate chews 
seem to be more appealing to the US consumers, a mix in the product range seems to be 
the best strategy for Olivio.  
Crocker explains that acquiring new customers and making them buy and consume more 
of their products is a challenge. When the ingredient royalty fees are high, this should be 
compensated with higher sales which is not the case for Olivio. He shares his views on 
customer acquisition costs and return on investment issues: 
“People in United States don’t care about eating healthy. People’s perception is 
relatively simplified and they focus more on the fat rates, or calories when they 
purchase something. Young generation (18-30) is more focusing on food quality. 
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Problem is how to economically grow the market because winning a customer is a 
challenge and it creates costs. In Benecol’s royalty model, ingredient price is ex-
pensive. Raisio might do the marketing activities themselves to attract more cus-
tomers. Because when one customer costs 25 USD and when they buy the product 
once a year, it is not profitable enough. Return on Investment is uncertain and it 
is the main problem. The customer acquisition costs should be lower and consum-
ers need to buy the products more.” 
It is possible to claim the cholesterol reduction by 10% in European markets but this is 
not allowed in USA. FDA claims that 2 grams of stanol and sterols may reduce the cho-
lesterol levels. As different type of products are more appealing to the consumers in dif-
ferent countries due to the cultural differences, innovator companies might need to recon-
sider their strategies and help licensing partners for new product development activities 
in specific countries. Support from innovator firms might be needed for either new prod-
uct development activities or marketing activities to allow the licensing partners to focus 
more on one of these aspects for more effective consumer awareness.  
4.6.2 Kalbe Nutritionals Indonesia 
Kalbe is one of the biggest pharmaceutical company in South East Asia and Kalbe Nutri-
tionals is the subsidiary of Kalbe Group. Kalbe Nutritionals is an Indonesian brand, which 
is active in healthy food and drink business. The goal of the company is to provide healthy 
products for people regardless of the age of the person. Their mission is to meet the nu-
trition requirements of active women and breastfeeding mothers, to support children’s 
early stage of growth and development, to improve adults’ and elders’ quality of life, and 
to support teens’ and modern professionals’ healthy lifestyle. They have several products 
in their product range to meet their goals. In order to capture their perspective on making 
business with Benecol and their marketing activities, an interview was conducted with 
Donny Bambang Iryanto, the business unit head of Kalbe Nutritionals.  
Kalbe Nutritionals’ partnership with Raisio and Benecol started in 2008 and since then, 
no other competitor entered to functional food business in Indonesia, making Kalbe Nu-
tritionals the market leader in their area. He explains the vision and mission of the com-
pany, the reason behind the partnership with Benecol, as well as their mindset of provid-
ing healthy foods for people from womb to tomb in his words: 
“The vision of Kalbe is to create and bring wellness to Indonesian people with its 
nutritional products and our vision is to strengthen the vision of Kalbe in the same 
context. Our mission is providing our products in each of the citizens' home. If we 
talk about our product range, we can describe it as from womb to tomb. Basically, 
we have nutrition for pregnancy period for women and the baby. After that, we 
provide nutrition for infants, teenagers, young adults, adults, seniors, and also 
special nutrition for people who have diabetes. Benecol concept and proposition 
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matches and fits exactly to Kalbe Nutritionals' mission. As cholesterol is one of the 
primary causes of coronary heart disease, we want to provide wellness in terms of 
cholesterol problem. This is why we see that it is very important to have a partner-
ship with Benecol. Since plant stanol ingredient of Benecol is acknowledged by 
institutions, healthcare professionals, and medical bodies and have the exclusivity, 
we wanted to use Benecol brand in our cholesterol lowering business.” 
In Kalbe Nutritionals case, the main driver of starting a partnership with Raisio and in-
corporating Benecol products in the product range was the uniqueness of the ingredient. 
Having the approval from reputable regulators for claiming health benefits of plant 
stanols enabled Benecol to become an appealing brand, since it is the only brand that can 
use and contain plant stanols.  
According to Iryanto, the competitive environment in functional foods in Indonesia 
doesn’t seem very tough. Kalbe Nutritionals is the only company in Indonesia that pro-
vides cholesterol lowering functional foods. There are few local brands using plant sterols 
in their products under supplement category and they are also claiming cholesterol reduc-
tion. However, these local brands are not permitted to claim the cholesterol reduction by 
percentage and cannot recommend the amount and duration of consumption, which gives 
an advantage to Kalbe Nutritionals as they can use the health claims on their smoothie, 
cereal, and latte Benecol products. Iryanto explains their advantage over their competitors 
and the increased consumer awareness after getting the permission for health claims in 
2014: 
“We are the only company in Indonesia that performs campaigns and educates 
people about the role of plant stanol ester. Non-direct competitors usually talk 
about beta-glucan or soluble fiber. There is no other global brand that exists in 
Indonesia in functional foods. After 2014, we have been able to claim the choles-
terol lowering effect on the packaging and due to that, people are now more aware 
that plant stanol ester helps lowering cholesterol by 10% in 2 to 3 weeks. We can 
say that around 60% of Indonesian adults with the age of over 25 is already aware 
of NutriBenecol. In terms of purchase, 10-15% of the people who are aware of the 
brand usually buy Benecol at least for one month. We still need to educate them 
because Benecol is not like medicine. ” 
The role of opinion leaders in Indonesia is divided between the government and 
healthcare institutions. Ministry of health and several opinion leaders in different loca-
tions that spread around the islands undertake the task of disseminating the health benefit 
information to healthcare professionals and public. They emphasize the prevention of 
non-communicable diseases and the cholesterol reduction. In order to draw attention to 
this issue, Kalbe Nutritionals started an initiative 3 years ago where they explain the ways 
of lowering cholesterol which would result in the prevention of coronary heart disease:  
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“One out of three Indonesian people has high cholesterol. In health insurances 
here, the biggest spent comes from the heart diseases. In the last 3 years, we have 
been conducting a campaign called Indonesia fight cholesterol and we reached 
75000 people, which was also published in social media. We have been supported 
by the doctors and cardiovascular associations, as well as health minister. How-
ever, some of the key opinion leaders don't want to be seen that they are supporting 
certain brands. In order to communicate our Benecol products here and to be sup-
ported by opinion leaders, we brought government, as well as ministry of health 
into the picture. Since Indonesia consists of thousands of islands, big islands usu-
ally have their own institutions and key opinion leaders. We need to get in touch 
with several key opinion leaders in several institutions in those different locations. 
Knowing each of the key opinion leader and building relationship with them is 
important.” 
As people in Indonesia tend to consume products in liquid form rather than in solid form 
such as margarines, Kalbe Nutritionals focus has been on the liquid products over the 
years. Among Indonesian people, it is still not common to use margarine nor olive oils. 
Iryanto points out that in Indonesia, functional foods are still in the early stage, and Yakult 
and Benecol are the biggest players in the market. He states that functional foods will still 
play a key role in the healthy lifestyle of Indonesian people and business opportunities 
are compelling. 
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5. SUMMING UP RESULTS AND DISCUSSION 
The research and interviews are conducted to provide answers to the research questions 
that are presented in the thesis. The research questions are aimed to discover the relevant 
stakeholders affecting the commercialization outcomes of an innovation, to discover the 
activities they perform for several purposes, and to find out their motives, goals and in-
terests in their collaboration with relevant actors. In order to study the influence of stake-
holders on success of commercialization of an innovation, case study method was used 
and relevant actors around the case company in functional food industry, their activities 
and their motives were analyzed. Four sub-questions are answered throughout the thesis, 
backed with theoretical and empirical research. The sub-questions are: 
 Who are the relevant stakeholders that can contribute to commercialization? 
 What kind of activities do stakeholders employ for effective commercialization? 
 What are the motives of stakeholders to be involved in along commercialization? 
 How stakeholders and their activities are interconnected?  
The case study results show that commercialization of an innovation in functional food 
industry requires activities from various stakeholders, including regulatory bodies (Min-
istry of Agriculture and Forestry, Evira, European Food Safety Authority), research or-
ganizations (VTT), primary healthcare professionals in different countries, opinion lead-
ers (e.g. leading doctors having opinion leader status in the focal context), scientists and 
licensing partners (e.g. Olivio USA, Kalbe Indonesia). Interactions between them are il-
lustrated in Figure 12 below. 
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Figure 12. Interactions between actors. 
Involving all stakeholders from the public and private sectors to academia and civil soci-
ety is a requirement for companies who want to successfully commercialize their prod-
ucts. In our case, innovator company has been actively involving the actors for the diffu-
sion of the innovation. Licensing partners are in close touch with the users by promoting 
the products. Innovator company uses media to reach users. Opinion leaders and scientists 
influence regulators to make decisions and they inform them about the scientific validity 
of the innovation and the public preference. Apart from these actors, the role of media 
and lead users can’t be ignored. Mass media is one of the most effective tools to help an 
innovation to diffuse. The fourth industrial revolution we have been experiencing is dig-
italizing and changing the way we interact with products, people, machines and recent 
developments daily. The use of social media and digital marketing practices is having 
considerable impact on the diffusion of innovations. The rapid advancements and evolu-
tion of the systems are causing disruptions almost in every industry and in every country, 
which is constantly changing the physical, digital, and biological ecosystems with an ex-
ponential growth. Companies are forced to adapt to new patterns of consumer behavior 
to market and deliver products and services.  
In functional foods industry, these stakeholders perform activities such as drafting new 
legislation and food labelling for health claims, conducting safety assessments, ingredient 
or product development, conducting surveys to find out consumers’ food preferences,  
communicating health benefits of the product to several actors for adoption, and gaining 
the trust of healthcare professionals and patients. This study revealed that the motives of 
such activities are ensuring well-being of people, creating new business ecosystems, con-
tributing to the economy, and creating awareness among public towards a healthy diet 
and lifestyle, which facilitate the emergence of a market. The stakeholders, their activities 
and motivations are illustrated in Figure 13 below. 
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Figure 13. Main stakeholders around the innovator firm in functional food industry in Finland. 
In this case study, in the later stage of commercialization process, the innovator firm have 
closer relationships and collaboration with the scientists, opinion leaders, and licensing 
partners with the aim of distributing the innovation to various geographies and maintain-
ing a robust position in foreign markets. Although regulators have an important role in 
the value chain and affect the processes by forming regulations and legislations, they 
usually act as an outside influencer who do not have constant communication and inter-
action with the innovator firm in the later stage of commercialization. This is due to the 
emerging presence of Benecol in foreign countries in which the licensing partner is re-
sponsible for registering the product and communicating with the authorities. However, 
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in the beginning phase of commercialization, the role of regulators is crucial and it is 
necessary for innovator firms to communicate with regulators regarding the requirements 
of country policies when launching and marketing a product. The proximity between in-
novator and actors in the later stage of commercialization is illustrated in Figure 14 below. 
 
Figure 14.   Proximity between innovator and actors in functional food industry in Finland. 
In this case study, EFSA, EVIRA, and MMM acted as the major regulatory forces, since 
the innovation is originated in Finland and EVIRA and MMM are the organizations that 
are responsible for the legislative matters and risk assessments in Finland. Scientists and 
opinion leaders acted as disseminators in terms of educating the healthcare professionals 
and public in Finland and also in many countries. They contributed to the scientific re-
search and revealed the medical effects of the ingredient. They gave speeches in seminars 
and conferences around the world to present the health benefits of the ingredient and to 
address the importance of an active lifestyle, which promoted the innovator firm’s cause 
of providing a healthy living and reducing cholesterol. Licensing partners incorporated 
Benecol products in their product range with the constant support and guidance from the 
innovator firm in terms of ingredient, data, ideas, and problem solving. These activities 
and achievements facilitated the diffusion of the innovation throughout the world and 
made the innovation one of the most successful examples in functional food category.  
The research questions of the thesis, the stakeholders involved, their activities, motives, 
and the interactions between them are listed in the Table 11 below. 
 
  
65 
Table 11. Answers to research questions. 
Regulators Opinion Leaders Innovator Licensing Partners Scientist
• Ministry of Agriculture and Forestry 
• EFSA 
• EVIRA 
• EU Commission
Pekka Puska and other 
individuals, organizations abroad
Raisio
• Olivio USA 
• Kalbe Nutritionals Indonesia
Helena Gylling
RQ2 - What kind of activities do stakeholders 
employ for effective commercialization?
• Regulating the marketing of a food 
product 
• Providing guidance to the 
manufacturers on the authorization 
procedure
• Conducting and evaluating risk and 
safety assesments
• Ensuring the validity of the health 
claims 
• Trusting the product, 
promoting and disseminating its 
use by cooperating with 
manufacturers, and influencing 
major healthcare actors
• Attending the seminars and 
conferences worldwide to give 
speeches about the health 
benefits of the ingredient
Communicating the health benefits of 
the products to several healthcare 
professionals around the world for 
adoption
Distributing products in overseas and 
making them available for users
Validating the health claims and 
revealing positive health effects of the 
ingredient, collaborating with 
innovators
RQ3 - What are the motives of stakeholders 
to be involved in along commercialization?
Well being of people as the health is a 
concern in functional food products
Well being of people and 
improving healthy lifestyle of a 
population
Well being of people as well as 
worldwide product adoption 
Well being of people and reaching more 
consumers for revenue increase
Well being of people, contributing to 
the scientific field they are involved in 
with the collaboration with innovators
RQ4 - How stakeholders and their 
activities are interconnected? 
Regulators are in close touch with 
innovators in the beginning stage of 
commercialization to ensure that 
ingredients comply with the  
guidelines
Collaboration with food 
manufacturers for reducing the 
fat content created awareness 
among public towards a healthy 
diet, which increased the 
credibility of Benecol
Being a central focal actor in the 
network, innovator orchestrates the 
members of the ecosystem by 
continuous information flow
Constant communication between 
licensing partners and innovator provides 
improved management and marketing 
practices
• Contribution from scientists helped 
innovator company to obtain the 
approval of health claims from 
regulators
• The revealed positive health effects 
of plant stanols enabled innovator 
company to increase the product's 
sales price against its competitor
RQ1 - Who are the relevant stakeholders 
that can contribute to commercialization?
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Users of the innovation can also contribute to research and development activities by giving feedback about the products’ strengths and weaknesses. It is emphasized that the competence to involve the right users at the right time in the right form is a valuable as-set for innovator firms. However, these users must have a high motivation toward new solutions, they should be open to new technologies, and they should be embedded into a supportive environment (Lettl, 2007). It is pointed out that the users can be also innova-tors when they are in need of the products or services that are not yet available in the market conditions. Therefore, these users take the initiative and come up with their own solutions, which results in an innovation that might disrupt current technologies. It is stated that their motivation to innovate comes from the high benefit the solution would provide. In order to be successful when coming up with a new user innovation, follow-ing patterns are emphasized (Hienerth & Lettl, 2011): 
 Need for a new solution 
 Exploring the community 
 Building a micro community 
 Leveraging the micro community 
 Tapping into the macro community 
 Early market development 
 Emergence of standard equipment 
It can be seen that community plays an important role in opportunity evaluation and de-
velopment of a new innovation. The lead users share their ideas with their peers in the 
community to get feedback. By doing this, the user innovators can evaluate their ideas 
and make modifications to meet the needs. Lead users address niche segments instead of 
larger market segments unlike mass market manufacturing firms, as the innovation ideas 
mostly appeal to other early adopters who have more specific needs and are encountering 
more problems than an average user. As the close community members get involved in 
the process who have technical and required skills for the innovation to be developed, a 
micro community starts to take shape around the innovation ideas. However, it is noted 
that the higher reputation of a lead user influences community members positively and 
generates bias to give feedback on their ideas, which might inhibit the diffusion of a po-
tentially successful idea of an unknown lead user (Hienerth & Lettl, 2011). When pro-
moting the innovation in the community, the community members should be familiar with 
the idea and they should understand the need. This helps an innovation to advance to the 
next level.  
One of the most serious barriers for user innovations to diffuse is lack of funds and small 
market segments. These barriers hinder the innovation to advance to the early majority segment, which might be as well called crossing the chasm problem. In Hienerth and 
Lettl’s study (2011), it was pointed out that these challenges can be overcome by proving 
the superiority of the innovation by personally using them. In addition to that, once the 
opinion leaders and early adopters start to use the innovation, this helps the innovation to 
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draw attention and diffuse into larger segments in the community, which easily creates a 
pull effect. 
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6. CONCLUSIONS 
6.1 Theoretical Contribution 
This study contributes to marketing and innovation management literature by developing 
knowledge on the relevance of diverse stakeholders in commercialization. The study also 
generates practical advice for managers who market and commercialize (radical) innova-
tions, beyond food innovations and a functional food industry. Findings have validated 
and contributed to the existing studies (Mark-Herbert, 2004; Matthyssens et. al., 2008; 
Öberg & Shih, 2014; Aarikka-Stenroos et al., 2014; Hillebrand et. al., 2015; Granqvist & 
Ritvala, 2016) that overly strict boundaries and regulations delayed the advancement of 
the functional food innovations. It also validates the research on how functional food 
innovations should develop over time in terms of managerial methods and creating added 
value. As it was studied, collaborative agreements, alliances and partnerships facilitate 
the progress of the innovation and help its dissemination in the world. This study supports 
that different types of actors influence each other in a commercialization process by 
sharing goals and getting involved in collaborative agreements, and that stakeholder mar-
keting capabilities have an impact on organizations' performance in the long-term and the 
impact is indirect.  
Benecol’s distribution around the world highly relies on the involvement of scientists’ 
and opinion leaders’ activities on ingredient experiments and revealing the positive health 
effects, as well as the communication of these health benefits in various conferences. It 
also depends on regulatory bodies approving the product in target markets, healthcare 
professionals educating the patients and endorsing this way of treatment, licensing 
partners distributing the products in their local markets to make the product available to 
users, and users adopting the product. Therefore, stakeholder marketing recognizes that 
customer relationships may be influenced by relationships with other stakeholders and 
that a diverse stakeholders co-creates value (Gummesson, 2008). 
The research addresses market-creation related challenges that organizations come across 
throughout the commercialization process such as regulatory issues, and influencing con-
sumers proactively to raise attraction to the novelty. It emphasizes the importance of sus-
tained collaboration between actors. 
6.2 Managerial Implications 
The research findings indicate that the focus of the activities should not only on research 
and development, but resources must be allocated to commercialization activities as well. 
In the beginning stage of commercialization of an innovation, managers should be in close 
contact with regulators to comply with the ingredient usage and packaging regulations. 
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The recommendations and guidelines of the relevant regulatory bodies should be fol-
lowed in order to experience a smooth and delay-free process of ingredient or product 
registration. In order to have a well-established position in the market, structured, sys-
tematic preparation and research about the markets, competitors, related actors that would 
be beneficial for the dissemination of the innovation should be studied in advance. Active 
collaborations with research organizations, scientists, and opinion leaders have an im-
portant role on creating credibility and building an image of a successful brand. Managers 
should note that diffusion of a radical innovation is not an easy task and it requires active 
involvement and contribution from various stakeholders. The key point here is to involve 
these stakeholders well in advance and to share the same goals and interests. In order to 
be on the same page with stakeholders that are considered to support the diffusion, open 
communication, and setting the common goals and mutual interests are important. The 
findings of this study indicate that when stakeholders have the same or similar motives 
for performing an activity and share the same goals, the outcome becomes more beneficial 
and satisfactory for all the parties involved. 
Partnerships with licensing partners in different countries would help innovator firms to 
diffuse in foreign markets with the help of their local partners who know the habits and 
preferences of the consumers. Managers should be aware that feedback from licensing 
partners on management and marketing practices, and new product activities would en-
hance the communication between two parties and might introduce new ways of doing 
business and task partitioning. Especially when entering a new market, regulations of the 
market should be well studied. Communication and constant information flow between 
licensing partners and the innovator company is essential and should not be neglected. As 
the TV and newspaper usage is dramatically diminishing in the recent years with the shift 
to smartphones, using digital solutions such as search engine optimization, Google Ad-
Words, and Facebook Ads for marketing purposes should be considered to reach consum-
ers, as they provide a massive database of users which would enable innovator firms to 
convey their causes. 
6.3 Limitations and Future Research 
This study explores the activities and motives of the major stakeholders that influence 
commercialization outcomes around an innovator firm in functional food industry. One 
limitation might be that the significance level of the key stakeholders might differ in other 
industries. Since there are many other type of minor stakeholders that have effect on the 
commercialization process at some degree, their activities and motives can be examined 
further. These stakeholders can be discovered through the interviews with other key man-
agers in the innovator firm, and an extensive web search can be conducted to identify the 
stakeholders in a longitudinal study. As the successful commercialization of a functional 
food innovation highly depends on multiple factors including the opinion leaders’ and 
healthcare professionals’ recommendations, identification of these key actors in different 
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geographies through licensing partners and conducting interviews to examine their impact 
on consumers’ buying decision process would provide broad insights on the case.  
Although media and digital marketing practices have an important role on influencing 
customers’ purchase decisions, the interviewees could not provide adequate and fruitful 
discussions on the matter due to their administrative positions and lack of knowledge 
about the marketing activities in general. The expansion of the qualitative interviews and 
their analysis would provide a more comprehensive, in-depth overview on the impact of 
the commercialization activities. In addition to this, the price difference of two major food 
product in cholesterol reduction category can be analyzed in more detail, which are Becel 
Proactiv and Benecol. The findings indicate that this price difference is caused by the 
conversion process of sterols to stanols. In order to derive stanols, a chemical conversion 
process is needed, which incurs costs and as a result, this reflect on the sales price. Even 
though the cholesterol lowering effect is almost at the same levels for both products, there 
is a substantial price difference between them. A user survey can be conducted to find out 
the reasons and drivers for choosing one functional food product over another to learn 
more about the consumer awareness and their preferences, which would also complement 
the research by adding the user point of view as another stakeholder category. Cost struc-
ture of Benecol margarine can be analyzed further to find out the factors that increase its 
price compared to its major competitor Becel Proactiv. In addition to these, as there is a 
new novel food regulation in EU, how regulators shape manufacturers’ innovation activ-
ities present an interesting area for further research. 
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